var title_f6_44_6848="Anterior exenteration specimen";
var content_f6_44_6848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior exenteration specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross fixed specimen from anterior exenteration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6848=[""].join("\n");
var outline_f6_44_6848=null;
var title_f6_44_6849="Coronary artery fistula occluder";
var content_f6_44_6849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Coronary artery fistula occluder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selective left coronary artery angiogram shows a dilated left circumflex coronary artery (LCx) with a fistula (arrow) to the right atrium (RA). Panel B shows a selective LCx coronary angiogram via a sheath (red arrow) introduced from the inferior vena cava to the LCX through the fistula. Note the patency of the last viable myocardial branch of the LCX (black arrow). Panel C shows a selective left coronary artery angiogram after the placement of an occlusion device (arrow); there is no residual shunting to the RA through the device. Note that the last viable myocardial branch remains patent (white arrow) and that there is enhanced blood flow to the other coronary artery branches after elimination of the steal (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6849=[""].join("\n");
var outline_f6_44_6849=null;
var title_f6_44_6850="Clubfoot infant";
var content_f6_44_6850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clubfoot in an infant with myelomeningocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6850=[""].join("\n");
var outline_f6_44_6850=null;
var title_f6_44_6851="First trim us cystic hygroma";
var content_f6_44_6851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester ultrasound showing a cystic hygroma that extends the entire length of an 11 week fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRL: crown rump length.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynn Simpson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6851=[""].join("\n");
var outline_f6_44_6851=null;
var title_f6_44_6852="Prednisolone and gentamicin: Drug information";
var content_f6_44_6852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone and gentamicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/22/21860?source=see_link\">",
"    see \"Prednisolone and gentamicin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/54/26466?source=see_link\">",
"    see \"Prednisolone and gentamicin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pred-G&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic/Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inflammatory conditions and superficial ocular infections:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Apply",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch ribbon into the conjunctival sac of the affected eye(s) 1-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Instill 1 drop into the conjunctival sac of the affected eye(s) 2-4 times/day; during the initial 24-48 hours, the dosing frequency may be increased if necessary up to 1 drop every hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If signs and symptoms do not improve after 2 days of treatment, the patient should be re-evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred-G&reg;: Prednisolone acetate 0.6% and gentamicin sulfate 0.3% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred-G&reg;: Prednisolone acetate 1% and gentamicin sulfate 0.3% (5 mL, 10 mL  [DSC]) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"     <b>",
"      Note:",
"     </b>",
"     Contact lenses should not be worn during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Apply into pocket between eyeball and lower lid; patient should look downward before closing eye. Do not touch tip of tube to eye.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Shake well before using. Tilt head back, instill into the conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation. Do not touch dropper to eye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of steroid responsive inflammatory conditions where either a superficial bacterial ocular infection or the risk of bacterial ocular infection exists",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Delayed wound healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Discomfort, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Glaucoma, intraocular pressure increased, optic nerve damage (infrequent), posterior subcapsular cataract formation, superficial punctate keratitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gentamicin, prednisolone, other aminoglycosides or corticosteroids, or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial or fungal infection of the eye",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Prolonged use of corticosteroids may result in glaucoma; damage to the optic nerve, defects in visual acuity and fields of vision, corneal and scleral thinning (leading to perforation), and posterior subcapsular cataract formation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataract surgery patients: Use following cataract surgery may delay healing or increase the incidence of bleb formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only. Do not inject subconjunctivally or introduce into the anterior chamber of the eye. A maximum of 20 mL of suspension or a maximum of 8 g of ointment should be prescribed initially; patients should be re-evaluated (eg, intraocular pressure and exams using magnification and fluorescein staining, where appropriate) prior to additional refills. Use &gt;10 days should include routine monitoring of intraocular pressure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13869803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F213035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F213034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Pred-G S.O.P. Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3-0.6% (3.5 g): $44.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pred-G Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3-1% (5 mL): $45.29",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Samples JR and Meyer SM, &ldquo;Use of Ophthalmic Medications in Pregnant and Nursing Women,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1988, 106(5):616-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/44/6852/abstract-text/2903673/pubmed\" id=\"2903673\" target=\"_blank\">",
"        2903673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trope GE, Lawrence JR, Hind VM, et al, \"Systemic Absorption of Topical and Subconjunctival Gentamicin,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 1979, 63(10):692-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/44/6852/abstract-text/508681/pubmed\" id=\"508681\" target=\"_blank\">",
"        508681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10069 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6852=[""].join("\n");
var outline_f6_44_6852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213037\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213049\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213038\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213039\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213015\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213029\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213028\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213047\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213032\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213018\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213046\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213022\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213023\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13869803\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213040\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213035\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213034\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213031\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/22/21860?source=related_link\">",
"      Prednisolone and gentamicin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/54/26466?source=related_link\">",
"      Prednisolone and gentamicin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_44_6853="Anatomy of ureters - male pelvis";
var content_f6_44_6853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Anatomy of ureters - male pelvis, cross section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the anatomy of the male pelvis and the cross sectional relationship of the ureters to the adjacent structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6853=[""].join("\n");
var outline_f6_44_6853=null;
var title_f6_44_6854="Pediatric cervical spine immobilization";
var content_f6_44_6854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediatric cervical spine immobilization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6854/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6854/contributors\">",
"     Alison Chantal Caviness, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6854/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6854/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6854/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6854/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/44/6854/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spine injury is rare in children. It is primarily seen in children who sustain blunt trauma, occurring in 1 to 2 percent of such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The injury may involve bones, ligaments, blood vessels, or the spinal cord, and must be rapidly recognized and treated to avoid permanent disability or death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cervical spine must be immobilized in any child who is suspected of having a cervical spine injury until the injury is excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/5\">",
"     5",
"    </a>",
"    ]. Immobilization should be established in the prehospital setting, or failing that, upon presentation to the health care facility. It should be continued until injury is ruled out clinically or radiographically [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/5\">",
"     5",
"    </a>",
"    ]. An estimated 3 to 25 percent of patients with spinal cord injury develop neurologic deficits caused by manipulation during resuscitation or transport [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ]. Extension of cervical cord injury can be avoided with proper immobilization and careful airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Techniques for immobilization of the cervical spine are reviewed here. The evaluation of cervical spine injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR IMMOBILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical spine must be immobilized if certain historical or physical examination features are present. Mechanisms of injury that are associated with a high risk of cervical spine injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe force (eg, motor vehicle crash or fall)",
"     </li>",
"     <li>",
"      Diving-related injuries",
"     </li>",
"     <li>",
"      Acceleration-deceleration injuries",
"     </li>",
"     <li>",
"      Sports injury (particularly hockey, football, and horseback riding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination features suggestive of cervical spine injury include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status (including intoxication or drowsiness)",
"     </li>",
"     <li>",
"      Inability to cooperate or verbalize",
"     </li>",
"     <li>",
"      Tenderness at the posterior midline of the cervical spine",
"     </li>",
"     <li>",
"      Decreased cervical range of motion",
"     </li>",
"     <li>",
"      Neurologic deficits",
"     </li>",
"     <li>",
"      Multiple system trauma",
"     </li>",
"     <li>",
"      Distracting injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to walk away from the scene of the injury does not negate the need for a cervical collar because some patients with cervical spine injuries can ambulate initially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     METHOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of cervical spine immobilization in children is influenced by their developmental anatomy. Compared with adults, children younger than eight years have relatively large heads, weak cervical muscles, and short necks. For the purpose of cervical spine immobilization, the term \"child\" refers to those younger than eight years and \"adult\" to those older than eight years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Anatomic considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immobilization devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection of the cervical spine to prevent extension of an existing spinal cord injury requires immobilization of the neck and the body. The neck is immobilized with a cervical collar, and the body is placed on a long spine board and secured with straps. The use of one of these devices without the other does little to prevent exacerbation of cervical cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cervical collars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical collars should be rigid and appropriately sized, and should not interfere with management of the airway. The appropriate collar size varies with the collar type; the user should follow the manufacturer's recommendations for sizing. As a general rule, high-cut collars are optimal because they provide points of support at the chin, angle of the jaw, and the mastoid processes.",
"   </p>",
"   <p>",
"    Many cervical collars are commercially available. The Stif-Neck&reg; (California Medical Products) extrication collar and the Philadelphia&reg; (Armstrong Industries) extrication collar are examples of collars that are available in sizes for children and adults; the ProSplint&reg; (Med Spec) cervical collar is available in infant sizes.",
"   </p>",
"   <p>",
"    Contraindications to cervical collar placement are the presence of fixed neck angulation, massive cervical swelling, or the need to perform cricothyrotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Spine boards",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cervical spine injury must be adequately secured to a backboard in order to fully immobilize the cervical spine. Children can be effectively immobilized on full or half-sized rigid spine boards; infants are better immobilized on half-sized rigid spine boards than in infant car seats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/8\">",
"     8",
"    </a>",
"    ]. Use of an intermediary device (eg, a half-sized spine board) may be necessary for extrication of adults and children who require a full-size spine board from a confined space (eg, a car).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neutral position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care must be taken to avoid flexion or extension of the neck when the patient is placed on the backboard. Neutral position is meant to maximize cervical spine protection but is not well defined. The most frequently cited definition is \"the normal anatomic position of the head and torso that one assumes when standing and looking straight ahead\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/10\">",
"     10",
"    </a>",
"    ]. The definition has been modified in children to a gaze preference perpendicular to the horizontal plane of the backboard [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/11\">",
"     11",
"    </a>",
"    ]. Some authors suggest that neutral position is maintained when the external auditory meatus is in line with the shoulder in the coronal plane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/12\">",
"     12",
"    </a>",
"    ]. The Advanced Trauma Life Support (ATLS) program defines the neutral position as \"supine without rotating or bending the spinal column\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults require occipital elevation to maintain the neutral position. No consensus regarding the amount of elevation exists; the range described in the literature varies from 1.3 to 9.5 cm, with most authors favoring approximately 2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. Correlation with spinal magnetic resonance imaging suggests that 2 cm of occipital padding provides a favorable ratio of spinal canal to spinal cord cross-sectional area [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the small number of patients studied limits the ability to generalize the results.",
"   </p>",
"   <p>",
"    Neutral positioning in children requires special allowance for their relatively large head size and is difficult to achieve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In particular, the prominent occiput in children and infants forces the cervical spine into flexion when the child is supine. Back boards that are used for children may be modified to facilitate the maintenance of neutral position [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/12\">",
"     12",
"    </a>",
"    ]. Some pediatric backboards have depressed areas for the occiput in order to maintain neutral position. Alternatively, the back can be elevated by the placement of padding under the shoulders and extending to the lumbar spine if one of these special boards is not available. In one prospective study of children younger than eight years, the mean back elevation needed to provide the neutral position was 2.5 cm (1 inch) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care must be taken in the immobilization of an obviously deviated cervical spine. The ATLS program recommends that any patient with an obvious deformity of the neck be kept in a neutral position. Reduction should only be attempted after appropriate imaging and by persons with expertise in cervical spine care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/13\">",
"     13",
"    </a>",
"    ]. Efforts should be made to place the neck in a neutral position unless doing so causes an increase in pain or muscle spasm, or leads to neurologic deficits or airway compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to cervical spine stabilization depends upon the position in which the patient is found. Patients who are found in the prone position must be log-rolled to the supine position for further evaluation and management.",
"   </p>",
"   <p>",
"    A rigid cervical collar should be applied before rolling the patient. The chin must fit securely into the chin cup of the collar. This will prevent flexion of the neck which causes the chin to slide down into the collar. The mandible should not be forced posteriorly. This could compromise the airway. The lower portion of the collar should rest firmly on the chest and clavicles. If there is not a commercially available collar which fits the child properly, a rolled towel can be placed around the neck, crossed in front of the neck over the chest and secured with tape.",
"   </p>",
"   <p>",
"    The cervical spine should be manually stabilized until the collar can be applied (",
"    <a class=\"graphic graphic_figure graphicRef80874 \" href=\"UTD.htm?14/2/14369\">",
"     figure 1",
"    </a>",
"    ). Care must be taken not to apply traction to the neck. Manual stabilization should be maintained until the body and head are fully immobilized on the spine board.",
"   </p>",
"   <p>",
"    The log-roll procedure maintains the spine in a neutral position during rolling and requires four people to properly perform in adults (",
"    <a class=\"graphic graphic_figure graphicRef60409 \" href=\"UTD.htm?11/32/11779\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/13\">",
"     13",
"    </a>",
"    ]. The ATLS Program does not specify the number of people needed for log-rolling a child. However, in log-rolling a child, having one person solely responsible for maintaining the cervical spine in the neutral position is critical. Two to four additional people may be needed, depending upon the size of the child.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helmets should be left in place unless they interfere with airway maintenance [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=see_link\">",
"       \"Field care and evaluation of the young athlete with acute neck injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fractures of the extremities should be immobilized before the patient is log-rolled.",
"     </li>",
"     <li>",
"      The arms are straightened and placed with palms inward next to the body.",
"     </li>",
"     <li>",
"      The legs are straightened and ankles secured to each other with padding between them.",
"     </li>",
"     <li>",
"      The patient is rolled with the body as a unit onto the center of the spine board.",
"     </li>",
"     <li>",
"      The board may be too wide for the child. Any gaps between the child and the edges of the board should be filled with towels or blankets to prevent side to side movement.",
"     </li>",
"     <li>",
"      The trunk, pelvis, lower extremities, and feet should be appropriately secured to the board. Straps must fit snugly enough to fix the body to the board but should not be so tight as to restrict respiration [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/19\">",
"       19",
"      </a>",
"      ]. Secure the feet first and then move toward the head.",
"     </li>",
"     <li>",
"      The patient's head and neck position are secured with tape across the forehead and cervical collar (",
"      <a class=\"graphic graphic_figure graphicRef59634 \" href=\"UTD.htm?9/25/9617\">",
"       figure 3",
"      </a>",
"      ). Tape should not be placed across the chin because it can interfere with airway management.",
"     </li>",
"     <li>",
"      Wedges are placed beside the head and neck to inhibit lateral movement. Lightweight head blocks are preferred to sandbag head stabilization. Sandbags increase the weight at the head end of the board and may cause a loss of the neutral position or a fall from the backboard [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AIRWAY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervical spine should be manually immobilized during airway management to prevent exacerbation of a spinal cord injury (",
"    <a class=\"graphic graphic_figure graphicRef80874 \" href=\"UTD.htm?14/2/14369\">",
"     figure 1",
"    </a>",
"    ). Initially, the airway can be opened with the jaw-thrust maneuver (",
"    <a class=\"graphic graphic_figure graphicRef53277 \" href=\"UTD.htm?42/28/43470\">",
"     figure 4",
"    </a>",
"    ). Orotracheal intubation with in-line manual stabilization provides the best approach to secure the airway in trauma victims without causing further cervical spine injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/13,20-22\">",
"     13,20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical airways are indicated in the presence of significant maxillofacial or laryngotracheal trauma. In children less than eight years of age, needle cricothyroidotomy or emergent tracheostomy are preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=see_link\">",
"     \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTINUED IMMOBILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's cervical spine must remain immobilized until a spinal cord injury has been excluded radiographically",
"    <strong>",
"     and",
"    </strong>",
"    clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6854/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the patient should be removed from the hard spine board as soon as possible to avoid unnecessary pain and pressure sores. This goal is commonly accomplished during the exposure portion of the primary survey when the patient is log-rolled for evaluation of the flank and back. Patients in whom significant concern for spinal cord injury exists and who may remain on the spine board for longer than 30 minutes, should have padding placed under the occiput, scapulae, sacrum, and heels (",
"    <a class=\"graphic graphic_figure graphicRef59634 \" href=\"UTD.htm?9/25/9617\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The scoop stretcher can be used to transfer the patient safely from the long board to the new surface, but it should not be used for continued immobilization. During transfer with the scoop stretcher, the stretcher is picked up at each end and supported in the center to prevent sagging and loss of neutral position. The patient then is secured to the new surface in the same manner as he or she was secured to the spine board.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29618948\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cervical spine must be immobilized in any child who is suspected of having a cervical spine injury until the injury is excluded. High-risk mechanisms include severe force, diving injuries, and sports injuries, particularly hockey, American football, and horseback riding. High-risk physical findings include altered mental status, midline neck pain, decreased cervical spine range of motion, and neurologic deficits. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immobilization devices include a cervical collar and a spine board (",
"      <a class=\"graphic graphic_figure graphicRef59634 \" href=\"UTD.htm?9/25/9617\">",
"       figure 3",
"      </a>",
"      ). Cervical collars should be rigid and appropriately sized, and should not interfere with management of the airway. The appropriate collar size varies with the collar type; the user should follow the manufacturer's recommendations for sizing. Patients with cervical spine injury must be adequately secured to a backboard initially in order to fully immobilize the cervical spine. Children can be effectively immobilized on full or half-sized rigid spine boards; infants are better immobilized on half-sized rigid spine boards than in infant car seats. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immobilization devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The child should be immobilized in the neutral position. Neutral positioning in children requires special allowance for their relatively large head size and is difficult to achieve. In particular, the prominent occiput in children and infants forces the cervical spine into flexion when the child is supine. Some pediatric backboards have depressed areas for the occiput in order to maintain neutral position. Alternatively, the back can be elevated by the placement of padding under the shoulders and extending to the lumbar spine if one of these special boards is not available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neutral position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When placing a child in a cervical collar, the cervical spine should be manually stabilized until the collar can be applied (",
"      <a class=\"graphic graphic_figure graphicRef80874 \" href=\"UTD.htm?14/2/14369\">",
"       figure 1",
"      </a>",
"      ). Care must be taken not to apply traction to the neck. Manual stabilization should be maintained until the body and head are fully immobilized on the spine board. Additional aspects of prehospital cervical spine immobilization are described. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a suspected cervical spine injury, the cervical spine should be manually immobilized during airway management to prevent exacerbation of a spinal cord injury (",
"      <a class=\"graphic graphic_figure graphicRef80874 \" href=\"UTD.htm?14/2/14369\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Airway management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's cervical spine must remain immobilized until a spinal cord injury has been excluded radiographically",
"      <strong>",
"       and",
"      </strong>",
"      clinically. However, the patient should be removed from the hard spine board as soon as possible to avoid unnecessary pain and pressure sores. This goal is commonly accomplished during the exposure portion of the primary survey when the patient is log-rolled for evaluation of the flank and back. The log-roll procedure maintains the spine in a neutral position during rolling and requires four people to properly perform in adults (",
"      <a class=\"graphic graphic_figure graphicRef60409 \" href=\"UTD.htm?11/32/11779\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Continued immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in whom significant concern for spinal cord injury exists and who may remain on the spine board for longer than 30 minutes, should have padding placed under the occiput, scapulae, sacrum, and heels (",
"      <a class=\"graphic graphic_figure graphicRef59634 \" href=\"UTD.htm?9/25/9617\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Continued immobilization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/1\">",
"      Riggins RS, Kraus JF. The risk of neurologic damage with fractures of the vertebrae. J Trauma 1977; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/2\">",
"      Patel JC, Tepas JJ 3rd, Mollitt DL, Pieper P. Pediatric cervical spine injuries: defining the disease. J Pediatr Surg 2001; 36:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/3\">",
"      Podolsky S, Baraff LJ, Simon RR, et al. Efficacy of cervical spine immobilization methods. J Trauma 1983; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/4\">",
"      Garfin SR, Shackford SR, Marshall LF, Drummond JC. Care of the multiply injured patient with cervical spine injury. Clin Orthop Relat Res 1989; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/5\">",
"      Skellett S, Tibby SM, Durward A, Murdoch IA. Lesson of the week: Immobilisation of the cervical spine in children. BMJ 2002; 324:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/6\">",
"      Bonadio WA. Cervical spine trauma in children: Part I. General concepts, normal anatomy, radiographic evaluation. Am J Emerg Med 1993; 11:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/7\">",
"      Hoffman JR, Mower WR, Wolfson AB, et al. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. N Engl J Med 2000; 343:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/8\">",
"      Huerta C, Griffith R, Joyce SM. Cervical spine stabilization in pediatric patients: evaluation of current techniques. Ann Emerg Med 1987; 16:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/9\">",
"      Perry SD, McLellan B, McIlroy WE, et al. The efficacy of head immobilization techniques during simulated vehicle motion. Spine (Phila Pa 1976) 1999; 24:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/10\">",
"      Schriger DL, Larmon B, LeGassick T, Blinman T. Spinal immobilization on a flat backboard: does it result in neutral position of the cervical spine? Ann Emerg Med 1991; 20:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/11\">",
"      Nypaver M, Treloar D. Neutral cervical spine positioning in children. Ann Emerg Med 1994; 23:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/12\">",
"      Herzenberg JE, Hensinger RN, Dedrick DK, Phillips WA. Emergency transport and positioning of young children who have an injury of the cervical spine. The standard backboard may be hazardous. J Bone Joint Surg Am 1989; 71:15.",
"     </a>",
"    </li>",
"    <li>",
"     Spine and spinal cord trauma. In: Manual of Advanced Trauma Life Support, 7th ed., American College of Surgeons, Chicago 2004. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/14\">",
"      De Lorenzo RA. A review of spinal immobilization techniques. J Emerg Med 1996; 14:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/15\">",
"      De Lorenzo RA, Olson JE, Boska M, et al. Optimal positioning for cervical immobilization. Ann Emerg Med 1996; 28:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/16\">",
"      Treloar DJ, Nypaver M. Angulation of the pediatric cervical spine with and without cervical collar. Pediatr Emerg Care 1997; 13:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/17\">",
"      Curran C, Dietrich AM, Bowman MJ, et al. Pediatric cervical-spine immobilization: achieving neutral position? J Trauma 1995; 39:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/18\">",
"      Aprahamian C, Thompson BM, Darin JC. Recommended helmet removal techniques in a cervical spine injured patient. J Trauma 1984; 24:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/19\">",
"      Manix T. The tying game. How effective are body-to-board strapping techniques? JEMS 1995; 20:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/20\">",
"      Gerling MC, Davis DP, Hamilton RS, et al. Effects of cervical spine immobilization technique and laryngoscope blade selection on an unstable cervical spine in a cadaver model of intubation. Ann Emerg Med 2000; 36:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/21\">",
"      Shatney CH, Brunner RD, Nguyen TQ. The safety of orotracheal intubation in patients with unstable cervical spine fracture or high spinal cord injury. Am J Surg 1995; 170:676.",
"     </a>",
"    </li>",
"    <li>",
"     King C, Rappaport LD. Emergent endotracheal intubation. In: The Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6854/abstract/23\">",
"      Sanchez JI, Paidas CN. Childhood trauma. Now and in the new millennium. Surg Clin North Am 1999; 79:1503.",
"     </a>",
"    </li>",
"    <li>",
"     King BR, Hagberg CA. Managements of the difficult airway. In: The Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.233.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6329 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-222.169.60.2-DB8828736C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6854=[""].join("\n");
var outline_f6_44_6854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29618948\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR IMMOBILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immobilization devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cervical collars",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Spine boards",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neutral position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AIRWAY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTINUED IMMOBILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29618948\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6329|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/2/14369\" title=\"figure 1\">",
"      Pediatric manual C-spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/32/11779\" title=\"figure 2\">",
"      Log-roll technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/25/9617\" title=\"figure 3\">",
"      Pediatric spine board",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/28/43470\" title=\"figure 4\">",
"      Jaw thrust",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=related_link\">",
"      Field care and evaluation of the young athlete with acute neck injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=related_link\">",
"      Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_44_6855="Prenatal ultrasound of ileal atresia with meconium pseudocyst";
var content_f6_44_6855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of ileal atresia with meconium pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sagittal ultrasound at 28 weeks of gestation shows several dilated loops of bowel.",
"    <br>",
"     (B) Axial image of the fetal abdomen shows a large cystic mass containing echogenic fluid anterior to dilated bowel loops consistent with a meconium pseudocyst.",
"     <br>",
"      (C) Newborn abdominal radiograph shows a mass containing air in the right midabdomen and dilated bowel loops to the left. Dilated small bowel loops surround the mass.",
"      <br>",
"       (D) Contrast enema shows a microcolon surrounding the air-filled meconium pseudocyst. At surgery an ileal atresia with perforation into a meconium pseudocyst was identified.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Courtesy of Dorothy I Bulas, MD.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6855=[""].join("\n");
var outline_f6_44_6855=null;
var title_f6_44_6856="Drug-induced myopathies";
var content_f6_44_6856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced myopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6856/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/44/6856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the precise incidence is unknown, drug-induced myopathy is among the most common causes of muscle disease. Drug-induced myopathy ranges from mild myalgias with or without mild weakness to chronic myopathy with severe weakness and to massive rhabdomyolysis with acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Over 150 agents have been associated with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced myopathy may result from several different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct myotoxicity &mdash; Examples include alcohol, cocaine, glucocorticoids, lipid-lowering drugs, antimalarials (which is associated with vacuolar myopathies),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (which is associated with vacuolar myopathies), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      (which causes a mitochondrial myopathy).",
"     </li>",
"     <li>",
"      Immunologically induced inflammatory myopathy &mdash; The myopathy associated with D-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      is an example of this mechanism.",
"     </li>",
"     <li>",
"      Indirect muscle damage &mdash; This problem can occur by a variety of mechanisms including drug-induced coma with subsequent ischemic muscle compression, drug-induced hypokalemia (eg, diuretics), drug-induced hyperkinetic states (eg, delirium tremens or seizures secondary to alcohol), dystonic states associated with phenothiazines, hyperthermia related to cocaine use, and the neuroleptic malignant syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some settings, multiple mechanisms may combine to produce muscle damage. As an example, alcoholic binges may precipitate hypokalemia, hypophosphatemia, coma, or agitation; in addition, direct muscle toxicity may also be present.",
"   </p>",
"   <p>",
"    Intramuscular injections, particularly repeated injections of opiates (eg, heroin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    ), may cause muscle damage with a fibrotic reaction that can result in muscle contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/6\">",
"     6",
"    </a>",
"    ]. Inadvertent intraarterial injections may cause ischemic necrosis of muscle tissue that is typically associated with livedoid skin changes or skin infarction (Nicolau syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DRUGS CAUSING DIRECT MYOTOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use can lead both to an acute myopathy and to a chronic myopathy that differ in alcohol consumption history, in demographics, and in clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acute myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute alcoholic myopathy usually occurs in the setting of longstanding alcoholism, within hours after a particularly severe alcoholic binge (often one lasting several days). The vast majority of reported cases have been among male alcoholics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/8\">",
"     8",
"    </a>",
"    ]. The severity of attacks varies from asymptomatic increases in creatine kinase (CK) to severe myopathy with rhabdomyolysis; acute alcoholic myopathy is one of the most common causes of nontraumatic rhabdomyolysis and acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/9\">",
"     9",
"    </a>",
"    ]. Recurrent episodes of acute myopathy can occur following bouts of binge drinking.",
"   </p>",
"   <p>",
"    The pathogenesis of acute myopathy probably involves the direct effect of alcohol or of one of its metabolites on muscle cell intermediary metabolism and on muscle cell membrane structure and function that affect transmembrane permeability of ions and water. Hypokalemia and hypophosphatemia, commonly seen in chronic alcoholics, may potentiate muscle toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28324?source=see_link\">",
"     \"Hypophosphatemia in the alcoholic patient\"",
"    </a>",
"    .) Although other causes of rhabdomyolysis commonly occur in alcoholics, including seizures, delirium tremens, and coma, acute myopathy can clearly occur in the absence of any of these factors.",
"   </p>",
"   <p>",
"    Acute myopathy appears to be related to the dose of alcohol ingested. This may explain why episodes of acute myopathy are more common during drinking binges accompanied by fasting. Starvation decreases alcohol metabolism and results in increased blood alcohol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/8\">",
"     8",
"    </a>",
"    ]. However, acute elevations of serum CK levels and myopathic histologic changes have been induced in normal volunteers given large doses of alcohol in the absence of malnutrition or starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients present with muscle cramps, tenderness, and, often, swelling. Muscle involvement is usually generalized, although there is a predilection for the calf muscles. CK and other muscle enzymes may be markedly elevated. Peak CK elevation may occur at the time of or several days after admission to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/11\">",
"     11",
"    </a>",
"    ]. It has been postulated that phosphate depletion associated with excessive alcohol consumption may be aggravated by refeeding in the hospital without first restoring muscle phosphate, which then leads to further muscle damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .) Muscle biopsy demonstrates muscle fiber necrosis with subsequent degeneration and regeneration.",
"   </p>",
"   <p>",
"    The typical course of acute alcoholic myopathy includes full recovery of muscle and renal function after cessation of alcohol intake and management of any complications of rhabdomyolysis. Recovery of muscle strength can be expected within days to weeks, even in individuals with recurrent attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chronic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic alcoholic myopathy presents with the gradual onset of diffuse, usually proximal, muscle weakness over a period of weeks to months. Diffuse muscle atrophy is common. Muscle pain and tenderness are usually absent. CK and other muscle enzymes typically are normal or are only mildly elevated, and myoglobinuric renal failure does not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Female alcoholics may be at increased risk for chronic myopathy. In one study, for example, females developed myopathy at lower cumulative doses of alcohol than male alcoholics even when corrected for body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/13\">",
"     13",
"    </a>",
"    ]. Chronic myopathy usually occurs in malnourished alcoholics, but it has been clearly observed in well-nourished ambulatory patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of chronic alcoholic myopathy is incompletely understood. Direct toxic effects of alcohol or of one of its metabolites on skeletal and cardiac muscle, chronic malnutrition, chronic disuse, and chronic electrolyte abnormalities all are likely to contribute to the onset of weakness and to type II fiber atrophy.",
"   </p>",
"   <p>",
"    Other sequelae of chronic alcoholism, including peripheral neuropathy, cirrhosis, and Wernicke&rsquo;s encephalopathy, are often present. There is also a close clinical and histologic correlation between the presence of chronic myopathy and the development of alcoholic cardiomyopathy; both correlate with total lifetime alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients with chronic myopathy have a history of recurrent acute alcoholic myopathy, although the latter does not seem to be a prerequisite for the former.",
"   </p>",
"   <p>",
"    In one study of 50 ambulatory chronic alcoholics, it was estimated that, among those who drank more than 13 kg per kilogram of body weight cumulative lifetime dose, more than one-half developed symptomatic chronic myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/14\">",
"     14",
"    </a>",
"    ]. This dose translates into approximately 12 oz (350 mL) of 86-proof whiskey a day for 20 years in a 70 kg man. No cases of myopathy occurred at lower cumulative doses.",
"   </p>",
"   <p>",
"    Muscle biopsy in chronic alcoholics almost universally demonstrates some ultrastructural abnormalities on electron microscopy even in the absence of clinically apparent weakness or of myopathic changes on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/14\">",
"     14",
"    </a>",
"    ]. Typical histologic findings in patients with chronic myopathy include increased fat accumulation and type II fiber atrophy that is indistinguishable from changes seen in glucocorticoid-induced myopathy or in disuse atrophy. Muscle fiber necrosis is either absent or minimal, as are inflammatory infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abstinence from alcohol may lead to recovery of muscle strength. In addition, serial biopsies in patients who abstain have shown significant improvement in the degree of type II muscle fiber atrophy over a period of 3 to 18 months; in the same report, those who continued to drink showed an increase in atrophy when rebiopsied 3 to 10 months later [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are a common cause of drug-induced myopathy. Muscle weakness associated with the use of glucocorticoids may complicate parenteral short-term and high-dose use, particularly in the setting of a critical illness. Longer-term use of moderate- or high-dose oral glucocorticoids may produce a more insidious onset of weakness. Critical illness myopathy and glucocorticoid-induced myopathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lipid-lowering drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-lowering drugs, primarily the statins, are another common cause of myopathy. Muscle injury due to statins, fibrates, and other lipid-lowering drugs is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle injury ranging from asymptomatic CK elevation to massive rhabdomyolysis with acute renal failure has been reported following cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Cocaine use is the most common cause of illicit drug-induced medical problems in the United States, including muscle disease. In one report, at least 5 percent of cocaine users presenting to one emergency department had evidence of muscle injury based upon CK elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct cocaine-induced muscle injury may result from the markedly increased sympathomimetic activity induced by cocaine. Severe arterial vasoconstriction can cause skeletal muscle ischemia and infarction in the same manner as cocaine-induced vasospasm causes myocardial, cerebral, skin, or digital infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/21\">",
"     21",
"    </a>",
"    ]. An alternative mechanism is cocaine-induced inhibition of the reuptake of catecholamines at alpha adrenergic receptors, which, in turn, leads to high intracellular calcium levels in muscle cells and to subsequent cell damage and rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine users with muscle injury usually present to emergency departments with other problems, including delirium, fever, seizure, cardiovascular collapse, or chest pain, and are found incidentally to have muscle involvement. In some cases, however, myalgias are an important presenting symptom. Muscle injury can occur after oral or intranasal cocaine use but may be more common after intravenous use or after smoking the alkaloid-free base (crack cocaine) because of the more rapid and higher blood levels of the drug achieved via those routes. Muscle injury can occur after a one-time use of the drug or after repeated use. The onset of muscle involvement is usually within hours after drug administration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CK elevation ranges from a few times normal to marked elevations of greater than 50,000",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    In one report, for example, the mean CK maximum elevation in 39 patients with cocaine-associated rhabdomyolysis was 12,187",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/16\">",
"     16",
"    </a>",
"    ]. The patients with the highest CK levels are at greatest risk for acute myoglobinuric renal failure. These individuals usually, but not always, have additional risk factors for rhabdomyolysis resulting from cocaine use, including marked fever, agitation, hypotension, seizures, coma, or concomitant use of heroin, amphetamines, or phencyclidine (drugs which are also associated with rhabdomyolysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antimalarial drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarial drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus have been reported to cause a toxic neuropathy, myopathy, and cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"     23",
"    </a>",
"    ]. Most of the case reports have involved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and (in one instance) amodiaquine have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/24\">",
"     24",
"    </a>",
"    ]. Myopathy is a rare complication of these drugs; one study estimated the incidence to be 1 in 100 patient-years, although this has not been confirmed by others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study identified 12 cases of hydroxychloroquine neuromyotoxicity that had been reported in the medical literature between 1965 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of antimalarial therapy prior to the onset of weakness varies widely from less than one year to more than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"     23",
"    </a>",
"    ]. The development of myopathy does not seem to relate to dose, as nearly all cases occur with use of standard doses.",
"   </p>",
"   <p>",
"    Antimalarial neuromyopathy is thought to be due to the accumulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    in lysosomes and to the subsequent inhibition of lysosomal enzymes. Phospholipid and glycogen then accumulate in the lysosomes, producing the characteristic myeloid and curvilinear bodies seen on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"     23",
"    </a>",
"    ]. (See below.)",
"   </p>",
"   <p>",
"    Patients with myopathy present with proximal muscle weakness, usually without muscle pain. Peripheral sensory abnormalities, including decreased vibratory sense and absent deep tendon reflexes, may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"     23",
"    </a>",
"    ]. Muscle enzymes may be normal or mildly elevated (usually not more than three to four times normal). Electromyography (EMG) shows both myopathic and neuropathic changes. Muscle biopsy reveals type II fiber atrophy, evidence of neurogenic muscle fiber atrophy, and vacuoles on light microscopy; electron microscopy shows curvilinear bodies and lysosomal proliferation. Nerve biopsy has shown evidence of a toxic neuropathy; curvilinear bodies have also been demonstrated in neural pericytes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimalarial cardiomyopathy may present as a conduction system abnormality or as congestive heart failure. The electrocardiogram shows nonspecific T-wave abnormalities, and echocardiography and cardiac catheterization show evidence of restrictive cardiomyopathy with thickened ventricular walls and with reduced ventricular cavity size [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/27\">",
"     27",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) shows evidence of a nonischemic cardiomyopathy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87852 \" href=\"UTD.htm?4/62/5091\">",
"     image 1",
"    </a>",
"    ). Endomyocardial biopsy shows changes similar to skeletal muscle, including degeneration of myocytes, which appear enlarged and markedly vacuolated on light microscopy, with cytoplasmic vacuoles and granules (",
"    <a class=\"graphic graphic_picture graphicRef87854 \" href=\"UTD.htm?41/49/42775\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef87853 \" href=\"UTD.htm?15/60/16326\">",
"     picture 2",
"    </a>",
"    ), and shows the presence on electron microscopy of numerous large, complex, secondary lysosomes with curvilinear bodies and myeloid bodies (",
"    <a class=\"graphic graphic_picture graphicRef87855 \" href=\"UTD.htm?9/23/9594\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weakness, neurologic deficits, and congestive heart failure resolve within months after discontinuation of the antimalarial drug [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/23,25,28\">",
"     23,25,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenothiazines and other antipsychotic drugs are associated with the neuroleptic malignant syndrome that is characterized by fever and by muscular rigidity and that may have elevation of CK indicative of muscle injury. The neuroleptic malignant syndrome is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromyopathy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    can occur in the setting of acute overdose or even in the setting of chronic administration in therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Typically, the patient with chronic colchicine neuromyopathy will have been treated with daily low-dose colchicine (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for months to years; in one documented case, however, myopathy occurred within two weeks of starting colchicine therapy at a dose of 0.6 mg three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    neuromyopathy is unknown. It is thought to be related to colchicine&rsquo;s known effect on microtubule function, leading to impaired axonal transport in peripheral nerves and to alteration of the muscle cytoskeleton that is necessary for the normal movement of lysosomes in the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/29\">",
"     29",
"    </a>",
"    ]. Chronic kidney disease leading to increased plasma colchicine levels appears to be the major risk factor for neuromyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/32\">",
"     32",
"    </a>",
"    ]. The risk is also increased in organ transplant recipients who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , which impairs the metabolism of colchicine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients typically present with proximal muscle weakness, often more prominent in the lower than upper extremities. CK levels are almost always elevated, usually 10-fold to 20-fold above normal. Electromyography and nerve conduction studies document myopathic changes and an accompanying axonal polyneuropathy that is usually asymptomatic or that causes mild sensory symptoms and diminished deep tendon reflexes. Myotonic discharges may be noted in some patients and have been correlated with clinical findings of myotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Muscle biopsy shows vacuolar changes in muscle cells that are seen best on frozen sections, since the vacuoles are often damaged by paraffin fixation. The vacuoles have been shown to be of lysosomal origin by special stains and by electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle weakness resolves, and CK levels return to normal within a few days to several weeks after discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . The neuropathy resolves more slowly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    neuromyopathy may be confused diagnostically with polymyositis. Distinguishing features include the presence of neuropathy by electrodiagnostic testing, as well as the appearance of vacuoles and the absence of inflammation in the muscle biopsy of patients treated with colchicine. In addition, rapid resolution of the myopathy after withdrawal of colchicine strongly supports the diagnosis and helps to avoid the unnecessary use of glucocorticoids (as would be indicated in polymyositis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antiretroviral drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    and other nucleoside reverse transcriptase inhibitors can produce a mitochondrial myopathy with elevated muscle enzymes and with weakness. This disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link&amp;anchor=H6#H6\">",
"     \"Muscle disease in HIV-infected patients\", section on 'NRTI myopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ipecac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of syrup of ipecac by patients with bulimia to cause vomiting and weight loss may cause muscle damage. In addition to effects on skeletal muscle, cardiotoxicity has also been observed with clinical manifestations of tachycardia, hypotension, and conduction defects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link&amp;anchor=H337797#H337797\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Skeletal muscle'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link&amp;anchor=H1012918#H1012918\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Ipecac-induced myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMMUNOLOGICALLY MEDIATED MYOTOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Interferon alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myositis complicating the use of interferon alpha, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    , has been suggested by several case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several autoimmune disorders have been associated with D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , including drug-induced systemic lupus erythematosus, Goodpasture&rsquo;s syndrome, myasthenia gravis, and an inflammatory myopathy that is clinically and histologically similar to polymyositis. Myopathy has been observed with the use of penicillamine in patients with rheumatoid arthritis, scleroderma, cystinuria, and Wilson&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one report, for example, penicillamine-induced myositis occurred in 1.2 percent of treated patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of myositis appears to bear no relationship either to daily dose or to the duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/41\">",
"     41",
"    </a>",
"    ]. It has been reported in patients who take as little as 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and in patients who have been on the drug for as long as six years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients present with symmetric proximal muscle weakness. Typical dermatomyositis rashes and dysphagia may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/40\">",
"     40",
"    </a>",
"    ]. Muscle enzymes are elevated. EMG shows myopathic changes, and muscle biopsy reveals perifascicular cellular infiltrates, as well as muscle fiber necrosis and regeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle weakness resolves, and muscle enzymes return to normal within a few weeks to months of stopping the drug plus treatment with high-dose glucocorticoids (40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day). In some cases, clinical recovery has occurred just by stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    without adding glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6856/abstract/41\">",
"     41",
"    </a>",
"    ]. We generally administer glucocorticoids if muscle weakness is severe and if there are no contraindications to their use. Unlike idiopathic dermatomyositis and polymyositis, penicillamine-induced myositis resolves completely and does not recur once the offending drug is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3785262\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced myopathy is among the most common causes of muscle disease. It ranges from mild myalgias with or without mild weakness to chronic myopathy with severe weakness and to massive rhabdomyolysis with acute renal failure. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-induced myopathy may result from several different mechanisms, including direct myotoxicity, immunologically induced inflammatory myopathy, indirect muscle damage, or a combination of multiple mechanisms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that may cause direct myotoxicity include (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Drugs causing direct myotoxicity'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alcohol (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Alcohol'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cocaine (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Cocaine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Glucocorticoids (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Glucocorticoids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lipid-lowering drugs (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Lipid-lowering drugs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Antimalarials (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Antimalarial drugs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Colchicine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Antiretroviral drugs'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol use can lead both to an acute myopathy and to a chronic myopathy that differ in alcohol consumption history, in demographics, and in clinical manifestations. Acute alcoholic myopathy usually occurs in the setting of longstanding alcoholism, within hours after a particularly severe alcoholic binge. Acute alcoholic myopathy is one of the most common causes of nontraumatic rhabdomyolysis and acute renal failure. Chronic alcoholic myopathy presents with the gradual onset of diffuse, usually proximal, muscle weakness over a period of weeks to months. Diffuse muscle atrophy is common. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute myopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle injury ranging from asymptomatic CK elevation to massive rhabdomyolysis with acute renal failure has been reported following cocaine use, which is the most common cause of illicit drug-induced medical problems in the United States, including muscle disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cocaine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that may cause an immunologically induced inflammatory myopathy include (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Immunologically mediated myotoxicity'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Interferon alpha (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Interferon alpha'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      D-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Penicillamine'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indirect muscle damage can occur by a variety of mechanisms, and, in some settings, multiple mechanisms may combine to produce muscle damage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/1\">",
"      Zuckner J. Drug-related myopathies. Rheum Dis Clin North Am 1994; 20:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/2\">",
"      Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J 1993; 69:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/3\">",
"      Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/4\">",
"      Lane RJ, Mastaglia FL. Drug-induced myopathies in man. Lancet 1978; 2:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/5\">",
"      Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/6\">",
"      von Kemp K, Herregodts P, Duynslaeger L, et al. Muscular fibrosis due to chronic intramuscular administration of narcotic analgesics. Acta Clin Belg 1989; 44:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/7\">",
"      Stricker BH, van Kasteren BJ. Diclofenac-induced isolated myonecrosis and the Nicolau syndrome. Ann Intern Med 1992; 117:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/8\">",
"      Haller RG, Knochel JP. Skeletal muscle disease in alcoholism. Med Clin North Am 1984; 68:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/9\">",
"      Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/10\">",
"      Song SK, Rubin E. Ethanol produces muscle damage in human volunteers. Science 1972; 175:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/11\">",
"      Lafair JS, Myerson RM. Alcoholic myopathy. With special reference to the significance of creatine phosphokinase. Arch Intern Med 1968; 122:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/12\">",
"      Martin F, Ward K, Slavin G, et al. Alcoholic skeletal myopathy, a clinical and pathological study. Q J Med 1985; 55:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/13\">",
"      Urbano-M&aacute;rquez A, Estruch R, Fern&aacute;ndez-Sol&aacute; J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/14\">",
"      Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/15\">",
"      Fernandez-Sola J, Estruch R, Grau JM, et al. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 1994; 120:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/16\">",
"      Roth D, Alarc&oacute;n FJ, Fernandez JA, et al. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med 1988; 319:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/17\">",
"      Herzlich BC, Arsura EL, Pagala M, Grob D. Rhabdomyolysis related to cocaine abuse. Ann Intern Med 1988; 109:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/18\">",
"      Pogue VA, Nurse HM. Cocaine-associated acute myoglobinuric renal failure. Am J Med 1989; 86:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/19\">",
"      Singhal PC, Rubin RB, Peters A, et al. Rhabdomyolysis and acute renal failure associated with cocaine abuse. J Toxicol Clin Toxicol 1990; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/20\">",
"      Brody SL, Wrenn KD, Wilber MM, Slovis CM. Predicting the severity of cocaine-associated rhabdomyolysis. Ann Emerg Med 1990; 19:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/21\">",
"      Zamora-Quezada JC, Dinerman H, Stadecker MJ, Kelly JJ. Muscle and skin infarction after free-basing cocaine (crack). Ann Intern Med 1988; 108:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/22\">",
"      Parks JM, Reed G, Knochel JP. Cocaine-associated rhabdomyolysis. Am J Med Sci 1989; 297:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/23\">",
"      Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987; 82:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/24\">",
"      Wittes R. Neuromyopathy associated with amodiaquine hydrochloride. CMAJ 1987; 137:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/25\">",
"      Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 1995; 34:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/26\">",
"      Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/27\">",
"      Iglesias Cubero G, Rodriguez Reguero JJ, Rojo Ortega JM. Restrictive cardiomyopathy caused by chloroquine. Br Heart J 1993; 69:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/28\">",
"      Ratliff NB, Estes ML, Myles JL, et al. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987; 316:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/29\">",
"      Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/30\">",
"      Uri DS, Biavis M. Colchicine neuromyopathy. J Clin Rheumatol 1996; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/31\">",
"      Schiff D, Drislane FW. Rapid-onset colchicine myoneuropathy. Arthritis Rheum 1992; 35:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/32\">",
"      Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991; 18:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/33\">",
"      Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996; 19:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/34\">",
"      Duarte J, Cabezas C, Rodr&iacute;guez F, et al. Colchicine-induced myopathy with myotonia. Muscle Nerve 1998; 21:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/35\">",
"      Vanin JR. Ipecac abuse--danger. J Am Coll Health 1992; 40:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/36\">",
"      Cirigliano G, Della Rossa A, Tavoni A, et al. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/37\">",
"      Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000; 17:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/38\">",
"      Hengstman GJ, Vogels OJ, ter Laak HJ, et al. Myositis during long-term interferon-alpha treatment. Neurology 2000; 54:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/39\">",
"      K&auml;lkner KM, R&ouml;nnblom L, Karlsson Parra AK, et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/40\">",
"      Halla JT, Fallahi S, Koopman WJ. Penicillamine-induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 1984; 77:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/41\">",
"      Carroll GJ, Will RK, Peter JB, et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987; 14:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6856/abstract/42\">",
"      Takahashi K, Ogita T, Okudaira H, et al. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 1986; 29:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5166 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6856=[""].join("\n");
var outline_f6_44_6856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3785262\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DRUGS CAUSING DIRECT MYOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acute myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chronic myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lipid-lowering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antimalarial drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ipecac",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMMUNOLOGICALLY MEDIATED MYOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Interferon alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3785262\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5166|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/62/5091\" title=\"diagnostic image 1\">",
"      MRI drug induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5166|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/49/42775\" title=\"picture 1\">",
"      Hydroxychloroquine-induced cardiomyopathy 400X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/60/16326\" title=\"picture 2\">",
"      Histopathology of cardiomyocytes with cytoplasmic vacuoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/23/9594\" title=\"picture 3\">",
"      EM hydroxychloroquine cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=related_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28324?source=related_link\">",
"      Hypophosphatemia in the alcoholic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_44_6857="Physiology of corticotropin-releasing hormone";
var content_f6_44_6857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of corticotropin-releasing hormone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6857/contributors\">",
"     George P Chrousos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6857/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6857/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/44/6857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypothalamic factor that increases corticotropin (ACTH) release from pituitary cells was discovered as an active principle in 1955 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 1981, ovine corticotropin-releasing hormone (CRH) was isolated and sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH is a 41-amino acid peptide that is the major physiologic ACTH secretagogue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. There is considerable sequence homology of CRH among species, particularly in the amino-terminal region, which is required for biologic activity. CRH belongs to a family of peptides that includes the nonmammalian sauvagine and urotensin I, the mammalian urocortins 1, 2 (stresscopin-related peptide, SRP), and 3 (stresscopin, SCP), the last three of which also are found in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. All of these peptides have activities similar to but also distinct from those of CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH is processed from a prepro-CRH molecule (196 amino acids in humans) from which it is cleaved at flanking basic amino acid pairs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/9\">",
"     9",
"    </a>",
"    ]. The single human CRH gene is located on chromosome 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/10\">",
"     10",
"    </a>",
"    ], those of human urocortins 1, 2, and 3 on chromosomes 2, 3, and 10 respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYNTHESIS AND DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH is synthesized by neurons in the parvocellular (small cell) division of the hypothalamic paraventricular nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/11\">",
"     11",
"    </a>",
"    ]. Their axons project to the median eminence, where CRH is secreted into the hypophysial portal blood. These neurons may also contain other ACTH secretagogues (eg, arginine vasopressin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/12\">",
"     12",
"    </a>",
"    ] and cholecystokinin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/13\">",
"     13",
"    </a>",
"    ]), opioid peptides (eg, met-enkephalin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/14\">",
"     14",
"    </a>",
"    ] and dynorphin-1-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/15\">",
"     15",
"    </a>",
"    ]), and PHI-27, a prolactin secretagogue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/14\">",
"     14",
"    </a>",
"    ], particularly after adrenalectomy. In addition, CRH is synthesized by anterior pituitary corticotrophs and acts in an autocrine or paracrine manner to stimulate ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH is also present in some oxytocin-containing neurons in the magnocellular (large cell) division of the paraventricular nuclei that project to the posterior pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, CRH is widely distributed throughout the brain and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/11,18\">",
"     11,18",
"    </a>",
"    ] and in peripheral tissues, such as the adrenal medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/19\">",
"     19",
"    </a>",
"    ], testis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/20\">",
"     20",
"    </a>",
"    ], ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/21\">",
"     21",
"    </a>",
"    ], gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/24\">",
"     24",
"    </a>",
"    ], skin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/25\">",
"     25",
"    </a>",
"    ], myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/26\">",
"     26",
"    </a>",
"    ], endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/27\">",
"     27",
"    </a>",
"    ], and placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of CRH and its two receptor types CRHR1 and CRHR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/29-32\">",
"     29-32",
"    </a>",
"    ] in the brain suggests that CRH functions as a neuromodulator. CRH also may have local autocrine or paracrine regulatory actions in other tissues. As an example, CRH inhibits chorionic gonadotropin-stimulated androgen production by the testis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/33\">",
"     33",
"    </a>",
"    ] and facilitates embryo implantation in the endometrium. Furthermore, CRH may act as a hormone in the hypophysial portal system and as a systemic hormone in the pregnant woman [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH acts on the anterior pituitary corticotrophs by binding to type 1 CRH cell-surface receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/30,35\">",
"     30,35",
"    </a>",
"    ] and activating adenylyl cyclase, thereby increasing intracellular cAMP concentrations. Cyclic AMP activates cAMP-dependent protein kinase A, increasing the influx of extracellular calcium via L-type calcium channels and the production of lipoxygenase metabolites of arachidonic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. This results in secretion of ACTH and other proopiomelanocortin (POMC)-derived peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/40\">",
"     40",
"    </a>",
"    ] and later in increased POMC gene transcription and POMC biosynthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/41\">",
"     41",
"    </a>",
"    ]. The type 1 CRH receptor gene (CRHR1, MIM# 122561) is located on chromosome 17q12-q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic CRH stimulation causes corticotroph hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/43\">",
"     43",
"    </a>",
"    ]. Corticotroph CRH receptor number may modulate the ACTH response. CRH receptor messenger RNA and number are transiently reduced in the anterior pituitary (but not in the brain) by the administration of CRH and arginine vasopressin (AVP), whose effects are additive, by immobilization stress, and by adrenalectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/44-50\">",
"     44-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of adrenalectomy appear to be mediated at least in part by increased hypothalamic AVP and CRH secretion and are reversed by replacement doses of glucocorticoids. However, high doses of glucocorticoids suppress pituitary CRH receptor messenger RNA and number. These complex effects on pituitary CRH receptor expression help modulate the plasma ACTH response to stress on the one hand or adrenal insufficiency on the other.",
"   </p>",
"   <p>",
"    CRH also stimulates pituitary intermediate lobe melanotrophs to synthesize POMC mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/51\">",
"     51",
"    </a>",
"    ] and secrete alpha-melanocyte-stimulating hormone (MSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CRH IN PLASMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of hypothalamic CRH to peripheral plasma CRH concentrations is small; most of the plasma CRH presumably comes from nonhypothalamic sources [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. However, under certain circumstances, such as insulin-induced hypoglycemia or during major surgery, small increments in plasma CRH concentrations may reflect hypothalamic CRH release [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/57\">",
"     57",
"    </a>",
"    ]. Plasma CRH concentrations increase markedly during the third trimester in pregnant women because the placenta secretes CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=see_link\">",
"     \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Binding protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH circulates in human plasma bound to a high-affinity binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], which reduces its bioactivity and increases its clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/62\">",
"     62",
"    </a>",
"    ]. In women with complicated pregnancies, plasma CRH-binding protein concentrations may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/63\">",
"     63",
"    </a>",
"    ] at the same time as plasma CRH concentrations are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Despite binding to this protein, the plasma half-life of CRH in humans is only four minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/66\">",
"     66",
"    </a>",
"    ]. A similar circulating binding protein has not been found in other species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/60\">",
"     60",
"    </a>",
"    ], except primates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovine CRH is used for most clinical studies because it does not bind to the binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/60\">",
"     60",
"    </a>",
"    ], has a plasma half-life of 55 min and, consequently, a prolonged duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .) Thus, the specific binding of human CRH to CRH-binding protein may facilitate the removal of CRH from plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REGULATION OF CRH SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothalamic CRH secretion is regulated by inputs from higher centers and is influenced by the circadian pacemaker, stress, and glucocorticoid negative feedback.",
"   </p>",
"   <p>",
"    Glucocorticoid negative feedback inhibition occurs at both the pituitary and hypothalamic levels, and perhaps at higher centers, such as the hippocampus. Interestingly, at the level of the central nucleus of the amygdala, glucocorticoids stimulate rather than inhibit CRH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the anterior pituitary, glucocorticoids inhibit both ACTH secretion and POMC gene transcription, resulting in greatly reduced POMC mRNA levels and POMC synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To a lesser extent, glucocorticoids decrease CRH mRNA and peptide levels in the hypothalamic paraventricular nuclei [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/72-74\">",
"       72-74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucocorticoids block the stimulatory effect of CRH on POMC gene transcription [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/75\">",
"       75",
"      </a>",
"      ] and acute ACTH release [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/38\">",
"       38",
"      </a>",
"      ], and inhibit anterior pituitary CRH receptor expression [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/46,76\">",
"       46,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucocorticoids stimulate placental CRH synthesis and secretion in primary cultures of human placenta in contrast to the glucocorticoid suppression of CRH expression in the hypothalamus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin-6 and CRH both participate in the hypothalamic-pituitary-adrenal axis response to inflammation and other stressors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leptin, which inhibits adrenal glucocorticoid biosynthesis, may also inhibit CRH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/79\">",
"       79",
"      </a>",
"      ]. Since glucocorticoids stimulate leptin secretion, this may represent another feedback loop regulating hypothalamic-pituitary-adrenal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTS ON PITUITARY HORMONE SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH increases the secretion of ACTH by the anterior lobe and of POMC-derived peptides by the intermediate lobe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anterior lobe ACTH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenously administered CRH produces a rapid, dose-dependent increase in plasma ACTH concentrations. This effect is specific; plasma concentrations of other anterior pituitary hormones, vasopressin, or catecholamines do not change [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/66,80\">",
"     66,80",
"    </a>",
"    ]. Human CRH is equipotent to ovine CRH, but because of its shorter circulating half-life, the duration of the elevation in plasma ACTH concentrations is shorter and the total amount of ACTH secreted is less [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/66,81\">",
"     66,81",
"    </a>",
"    ]. However, the serum cortisol responses are similar because the plasma ACTH responses to both human and ovine CRH are maximally stimulatory for the adrenal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACTH released by CRH stimulates the secretion of cortisol and other adrenal steroids, such as dehydroepiandrosterone (DHEA) and, transiently, aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. There is a very small if any sex or age difference in the plasma ACTH or serum cortisol response to CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/83-86\">",
"     83-86",
"    </a>",
"    ], but the serum DHEA response is reduced in elderly men and the serum cortisol response is blunted in obese subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/83,87\">",
"     83,87",
"    </a>",
"    ]. As compared with white subjects, black subjects have greater plasma immunoreactive but not bioactive ACTH responses after CRH; as a result, the serum cortisol responses are similar in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hour of day has little effect on the plasma ACTH response to CRH, but the response of serum cortisol is much greater in late afternoon or evening than in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/89\">",
"     89",
"    </a>",
"    ]. In healthy persons, a major factor influencing the magnitude of the plasma ACTH response to CRH is the serum cortisol concentration. The response to CRH varies inversely with the basal serum cortisol concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/89\">",
"     89",
"    </a>",
"    ] due to glucocorticoid inhibition of CRH action on the corticotrophs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, the ACTH response is increased during metyrapone-induced hypocortisolemia and reduced by glucocorticoid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH-deficient knockout mice lack a normal diurnal serum corticosterone rhythm and have severely impaired adrenocortical response to stress [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/78\">",
"     78",
"    </a>",
"    ]. Pituitary POMC mRNA and ACTH levels and plasma ACTH concentrations are not increased. Pituitary POMC mRNA levels increase in adrenalectomized CRH-deficient mice, but plasma ACTH concentrations do not, indicating that CRH is required to stimulate ACTH release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intermediate lobe POMC peptide secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A functional intermediate lobe exists only during fetal life and in late pregnancy in humans. Regulation of secretion of alpha-MSH, beta-endorphin (beta-END), and other POMC-derived peptides from the intermediate lobe differs from that in the anterior lobe. The secretion of these peptides is mainly under tonic inhibitory control by the hypothalamic neurotransmitter dopamine, and is not inhibited by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/92\">",
"     92",
"    </a>",
"    ]. Intermediate lobe hormone secretion is also inhibited by gamma-aminobutyric acid (GABA), another hypothalamic neurotransmitter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRH and beta-adrenergic agonists stimulate alpha-MSH secretion through a cAMP-mediated mechanism, which is inhibited by dopamine. Dopamine also enhances the expression of intermediate lobe CRH receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXTRAPITUITARY EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH has several peripheral and central actions that may be mediated by binding to both type 1 (a, b, c, d, e, f, g, h) and type 2-alpha, -beta, and -gamma CRH receptors and CRH-binding protein (",
"    <a class=\"graphic graphic_figure graphicRef80600 \" href=\"UTD.htm?23/57/24478\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/32,95-98\">",
"     32,95-98",
"    </a>",
"    ]. The type 2 CRH receptors are splice isoforms that differ in their amino-terminal sequences, tissue distribution, pharmacology (ie, their relative affinities for CRH, sauvagine, urotensin, and the urocortins), and, presumably, their function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/99\">",
"     99",
"    </a>",
"    ]. Type 2-beta and gamma CRH receptors are most abundantly expressed in the limbic system, for example, which suggests they may mediate the behavioral effects of CRH and the urocortins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased activity of the hypothalamic-pituitary-adrenal axis may play a role in insomnia. Twenty-four-hour ACTH and cortisol secretion was increased in six young men and five young women with chronic insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/100\">",
"       100",
"      </a>",
"      ]. The greatest increase was during the evening and first half of the night. In 12 middle-aged men, intravenous CRH given after sleep onset caused more wakefulness and allowed less slow wave sleep than in young men [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic administration of CRH causes mesenteric vasodilatation, which at high doses can result in hypotension and tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/80,102\">",
"       80,102",
"      </a>",
"      ], and stimulates respiration through a central effect [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intracerebroventricular injection of CRH activates the autonomic nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/104\">",
"       104",
"      </a>",
"      ], resulting in increased serum catecholamine, glucagon, and glucose concentrations, elevated blood pressure and heart rate, decreased gastric acid secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/105\">",
"       105",
"      </a>",
"      ], and behavioral changes in animals [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRH may modulate reproductive function, since it reduces sexual receptivity in female rats [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/107\">",
"       107",
"      </a>",
"      ], lowers serum luteinizing hormone concentrations by inhibiting the secretion of gonadotropin-releasing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/108\">",
"       108",
"      </a>",
"      ], and inhibits chorionic gonadotropin-stimulated testosterone production by cultured Leydig cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRH exerts multiple actions in gestation via binding to CRH type 1 receptors. It directly stimulates CRH-1 receptor synthesis and DHEA-S secretion by human fetal adrenocortical cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]. It regulates placental blood flow and prostaglandin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/112\">",
"       112",
"      </a>",
"      ], increases in myometrium during labor and potentiates oxytocin- and prostaglandin F2-alpha-induced myometrial contractility [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/26\">",
"       26",
"      </a>",
"      ], and facilitates parturition [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/112,113\">",
"       112,113",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis of spontaneous preterm birth\", section on 'Corticotropin-releasing hormone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CRH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urocortin are secreted by a number of other peripheral tissues including spleen, thymus, synovial epithelial cells, inflammatory cells, and peripheral nerve endings, and modulate the immune response via CRH type 1 and 2 receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/114-117\">",
"       114-117",
"      </a>",
"      ]. Urocortin, but not CRH, is present in gastric epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/118\">",
"       118",
"      </a>",
"      ]. Among their actions, CRH and urocortin modulate secretion of cytokines and proliferation of lymphocytes and macrophages and degranulation of mast cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/116,119\">",
"       116,119",
"      </a>",
"      ]. CRH and urocortin also have potent cardiovascular actions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRH and CRH-1 receptor are synthesized by human dermal fibroblasts and hair follicles; CRH and ACTH also stimulate cortisol production in the hair follicle and corticosterone production in dermal fibroblasts [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/121\">",
"       121",
"      </a>",
"      ]. CRH enhances lipid secretion from human sebocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6857/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticotropin-releasing hormone (CRH) is a 41-amino acid peptide hypothalamic factor that increases ACTH release from pituitary cells.",
"     </li>",
"     <li>",
"      CRH is synthesized by neurons in the parvocellular (small cell) division of the hypothalamic paraventricular nuclei. Their axons project to the median eminence, where CRH is secreted into the hypophysial portal blood.",
"     </li>",
"     <li>",
"      CRH circulates in human plasma bound to a high-affinity binding protein, which reduces its bioactivity and increases its clearance.",
"     </li>",
"     <li>",
"      Hypothalamic CRH secretion is regulated by inputs from higher centers and is influenced by the circadian pacemaker, stress, and glucocorticoid negative feedback.",
"     </li>",
"     <li>",
"      The ACTH released by CRH stimulates the secretion of cortisol and other adrenal steroids, such as dehydroepiandrosterone (DHEA) and, transiently, aldosterone. There is a small if any sex and age difference in the plasma ACTH and serum cortisol response to CRH.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/1\">",
"      GUILLEMIN R, ROSENBERG B. Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 1955; 57:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/2\">",
"      SAFFRAN M, SCHALLY AV. The release of corticotrophin by anterior pituitary tissue in vitro. Can J Biochem Physiol 1955; 33:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/3\">",
"      Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/4\">",
"      Rivier C, Brownstein M, Spiess J, et al. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology 1982; 110:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/5\">",
"      Vale W, Rivier C, Brown MR, et al. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/6\">",
"      Spiess J, Rivier J, Rivier C, Vale W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A 1981; 78:6517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/7\">",
"      Lederis K. Non-mammalian corticotropin release-stimulating peptides. Ann N Y Acad Sci 1987; 512:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/8\">",
"      Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology 1996; 137:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/9\">",
"      Shibahara S, Morimoto Y, Furutani Y, et al. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 1983; 2:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/10\">",
"      Arbiser JL, Morton CC, Bruns GA, Majzoub JA. Human corticotropin releasing hormone gene is located on the long arm of chromosome 8. Cytogenet Cell Genet 1988; 47:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/11\">",
"      Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983; 36:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/12\">",
"      Kiss JZ, Mezey E, Skirboll L. Corticotropin-releasing factor-immunoreactive neurons of the paraventricular nucleus become vasopressin positive after adrenalectomy. Proc Natl Acad Sci U S A 1984; 81:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/13\">",
"      Mezey E, Reisine TD, Skirboll L, et al. Role of cholecystokinin in corticotropin release: coexistence with vasopressin and corticotropin-releasing factor in cells of the rat hypothalamic paraventricular nucleus. Proc Natl Acad Sci U S A 1986; 83:3510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/14\">",
"      H&ouml;kfelt T, Fahrenkrug J, Tatemoto K, et al. The PHI (PHI-27)/corticotropin-releasing factor/enkephalin immunoreactive hypothalamic neuron: possible morphological basis for integrated control of prolactin, corticotropin, and growth hormone secretion. Proc Natl Acad Sci U S A 1983; 80:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/15\">",
"      Roth KA, Weber E, Barchas JD, et al. Immunoreactive dynorphin-(1-8) and corticotropin- releasing factor in subpopulation of hypothalamic neurons. Science 1983; 219:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/16\">",
"      Pecori Giraldi F, Cavagnini F. Corticotropin-releasing hormone is produced by rat corticotropes and modulates ACTH secretion in a paracrine/autocrine fashion. J Clin Invest 1998; 101:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/17\">",
"      Sawchenko PE, Swanson LW, Vale WW. Corticotropin-releasing factor: co-expression within distinct subsets of oxytocin-, vasopressin-, and neurotensin-immunoreactive neurons in the hypothalamus of the male rat. J Neurosci 1984; 4:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/18\">",
"      Olschowka JA, O'Donohue TL, Mueller GP, Jacobowitz DM. Hypothalamic and extrahypothalamic distribution of CRF-like immunoreactive neurons in the rat brain. Neuroendocrinology 1982; 35:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/19\">",
"      Nicholson WE, DeCherney GS, Jackson RV, Orth DN. Pituitary and hypothalamic hormones in normal and neoplastic adrenal medullae: biologically active corticotropin-releasing hormone and corticotropin. Regul Pept 1987; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/20\">",
"      Yoon DJ, Sklar C, David R. Presence of immunoreactive corticotropin-releasing factor in rat testis. Endocrinology 1988; 122:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/21\">",
"      Mastorakos G, Webster EL, Friedman TC, Chrousos GP. Immunoreactive corticotropin-releasing hormone and its binding sites in the rat ovary. J Clin Invest 1993; 92:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/22\">",
"      Nieuwenhuyzen Kruseman AC, Linton EA, Ackland J, et al. Heterogeneous immunocytochemical reactivities of oCRF-41-like material in the human hypothalamus, pituitary and gastrointestinal tract. Neuroendocrinology 1984; 38:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/23\">",
"      Suda T, Tomori N, Tozawa F, et al. Distribution and characterization of immunoreactive corticotropin-releasing factor in human tissues. J Clin Endocrinol Metab 1984; 59:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/24\">",
"      Petrusz P, Merchenthaler I, Maderdrut JL, et al. Corticotropin-releasing factor (CRF)-like immunoreactivity in the vertebrate endocrine pancreas. Proc Natl Acad Sci U S A 1983; 80:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/25\">",
"      Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J 2001; 15:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/26\">",
"      Clifton VL, Telfer JF, Thompson AJ, et al. Corticotropin-releasing hormone and proopiomelanocortin-derived peptides are present in human myometrium. J Clin Endocrinol Metab 1998; 83:3716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/27\">",
"      Di Blasio AM, Pecori Giraldi F, Vigan&ograve; P, et al. Expression of corticotropin-releasing hormone and its R1 receptor in human endometrial stromal cells. J Clin Endocrinol Metab 1997; 82:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/28\">",
"      Grino M, Chrousos GP, Margioris AN. The corticotropin releasing hormone gene is expressed in human placenta. Biochem Biophys Res Commun 1987; 148:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/29\">",
"      De Souza EB. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 1987; 7:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/30\">",
"      Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 1993; 90:8967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/31\">",
"      Potter E, Sutton S, Donaldson C, et al. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A 1994; 91:8777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/32\">",
"      Stenzel P, Kesterson R, Yeung W, et al. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995; 9:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/33\">",
"      Ulisse S, Fabbri A, Dufau ML. Corticotropin-releasing factor receptors and actions in rat Leydig cells. J Biol Chem 1989; 264:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/34\">",
"      Makrigiannakis A, Zoumakis E, Kalantaridou S, et al. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol 2001; 2:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/35\">",
"      Millan MA, Samra AB, Wynn PC, et al. Receptors and actions of corticotropin-releasing hormone in the primate pituitary gland. J Clin Endocrinol Metab 1987; 64:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/36\">",
"      Gigu&egrave;re V, Labrie F, C&ocirc;t&eacute; J, et al. Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. Proc Natl Acad Sci U S A 1982; 79:3466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/37\">",
"      Won JG, Orth DN. Roles of intracellular and extracellular calcium in the kinetic profile of adrenocorticotropin secretion by perifused rat anterior pituitary cells. I. Corticotropin-releasing factor stimulation. Endocrinology 1990; 126:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/38\">",
"      Oki Y, Peatman TW, Qu ZC, Orth DN. Effects of intracellular Ca2+ depletion and glucocorticoid on stimulated adrenocorticotropin release by rat anterior pituitary cells in a microperifusion system. Endocrinology 1991; 128:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/39\">",
"      Won JG, Orth DN. Role of lipoxygenase metabolites of arachidonic acid in the regulation of adrenocorticotropin secretion by perifused rat anterior pituitary cells. Endocrinology 1994; 135:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/40\">",
"      Watanabe T, Orth DN. Detailed kinetic analysis of adrenocorticotropin secretion by dispersed rat anterior pituitary cells in a microperifusion system: effects of ovine corticotropin-releasing factor and arginine vasopressin. Endocrinology 1987; 121:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/41\">",
"      Lundblad JR, Roberts JL. Regulation of proopiomelanocortin gene expression in pituitary. Endocr Rev 1988; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/42\">",
"      Vamvakopoulos NC, Sioutopoulou TO. Human corticotropin-releasing hormone receptor gene (CRHR) is located on the long arm of chromosome 17 (17q12-qter). Chromosome Res 1994; 2:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/43\">",
"      Gertz BJ, Contreras LN, McComb DJ, et al. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 1987; 120:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/44\">",
"      Wynn PC, Harwood JP, Catt KJ, Aguilera G. Regulation of corticotropin-releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF receptors and corticotroph responses. Endocrinology 1985; 116:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/45\">",
"      Hauger RL, Millan MA, Catt KJ, Aguilera G. Differential regulation of brain and pituitary corticotropin-releasing factor receptors by corticosterone. Endocrinology 1987; 120:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/46\">",
"      Holmes MC, Catt KJ, Aguilera G. Involvement of vasopressin in the down-regulation of pituitary corticotropin-releasing factor receptors after adrenalectomy. Endocrinology 1987; 121:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/47\">",
"      Wynn PC, Harwood JP, Catt KJ, Aguilera G. Corticotropin-releasing factor (CRF) induces desensitization of the rat pituitary CRF receptor-adenylate cyclase complex. Endocrinology 1988; 122:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/48\">",
"      Hauger RL, Millan MA, Lorang M, et al. Corticotropin-releasing factor receptors and pituitary adrenal responses during immobilization stress. Endocrinology 1988; 123:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/49\">",
"      Hauger RL, Aguilera G. Regulation of pituitary corticotropin releasing hormone (CRH) receptors by CRH: interaction with vasopressin. Endocrinology 1993; 133:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/50\">",
"      Pozzoli G, Bilezikjian LM, Perrin MH, et al. Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures. Endocrinology 1996; 137:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/51\">",
"      Loeffler JP, Kley N, Pittius CW, H&ouml;llt V. Corticotropin-releasing factor and forskolin increase proopiomelanocortin messenger RNA levels in rat anterior and intermediate cells in vitro. Neurosci Lett 1985; 62:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/52\">",
"      Proulx-Ferland L, Labrie F, Dumont D, et al. Corticotropin-releasing factor stimulates secretion of melanocyte-stimulating hormone from the rat pituitary. Science 1982; 217:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/53\">",
"      Orth DN. Corticotropin-releasing hormone in humans. Endocr Rev 1992; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/54\">",
"      Sasaki A, Sato S, Murakami O, et al. Immunoreactive corticotropin-releasing hormone present in human plasma may be derived from both hypothalamic and extrahypothalamic sources. J Clin Endocrinol Metab 1987; 65:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/55\">",
"      Bruhn TO, Engeland WC, Anthony EL, et al. Corticotropin-releasing factor in the dog adrenal medulla is secreted in response to hemorrhage. Endocrinology 1987; 120:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/56\">",
"      Cunnah D, Jessop DS, Besser GM, Rees LH. Measurement of circulating corticotrophin-releasing factor in man. J Endocrinol 1987; 113:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/57\">",
"      Ellis MJ, Schmidli RS, Donald RA, et al. Plasma corticotrophin-releasing factor and vasopressin responses to hypoglycaemia in normal man. Clin Endocrinol (Oxf) 1990; 32:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/58\">",
"      Sasaki A, Shinkawa O, Margioris AN, et al. Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery. J Clin Endocrinol Metab 1987; 64:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/59\">",
"      Campbell EA, Linton EA, Wolfe CD, et al. Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab 1987; 64:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/60\">",
"      Orth DN, Mount CD. Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem Biophys Res Commun 1987; 143:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/61\">",
"      Potter E, Behan DP, Fischer WH, et al. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991; 349:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/62\">",
"      Linton EA, Wolfe CD, Behan DP, Lowry PJ. A specific carrier substance for human corticotrophin releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity. Clin Endocrinol (Oxf) 1988; 28:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/63\">",
"      Petraglia F, Florio P, Benedetto C, et al. High levels of corticotropin-releasing factor (CRF) are inversely correlated with low levels of maternal CRF-binding protein in pregnant women with pregnancy-induced hypertension. J Clin Endocrinol Metab 1996; 81:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/64\">",
"      Jeske W, Soszy��ski P, Lukaszewicz E, et al. Enhancement of plasma corticotropin-releasing hormone in pregnancy-induced hypertension. Acta Endocrinol (Copenh) 1990; 122:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/65\">",
"      Laatikainen T, Virtanen T, Kaaja R, Salminen-Lappalainen K. Corticotropin-releasing hormone in maternal and cord plasma in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1991; 39:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/66\">",
"      Sch&uuml;rmeyer TH, Avgerinos PC, Gold PW, et al. Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. J Clin Endocrinol Metab 1984; 59:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/67\">",
"      Xu J, Hennebold JD, Stouffer RL. Dynamic expression and regulation of the corticotropin-releasing hormone/urocortin-receptor-binding protein system in the primate ovary during the menstrual cycle. J Clin Endocrinol Metab 2006; 91:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/68\">",
"      Nicholson WE, DeCherney GS, Jackson RV, et al. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. J Clin Endocrinol Metab 1983; 57:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/69\">",
"      DeBold CR, DeCherney GS, Jackson RV, et al. Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 1983; 57:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/70\">",
"      Woods RJ, Grossman A, Saphier P, et al. Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. J Clin Endocrinol Metab 1994; 78:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/71\">",
"      Makino S, Gold PW, Schulkin J. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res 1994; 640:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/72\">",
"      Davis LG, Arentzen R, Reid JM, et al. Glucocorticoid sensitivity of vasopressin mRNA levels in the paraventricular nucleus of the rat. Proc Natl Acad Sci U S A 1986; 83:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/73\">",
"      Itoi K, Mouri T, Takahashi K, et al. Suppression by glucocorticoid of the immunoreactivity of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of rat hypothalamus. Neurosci Lett 1987; 73:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/74\">",
"      Beyer HS, Matta SG, Sharp BM. Regulation of the messenger ribonucleic acid for corticotropin-releasing factor in the paraventricular nucleus and other brain sites of the rat. Endocrinology 1988; 123:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/75\">",
"      Eberwine JH, Jonassen JA, Evinger MJ, Roberts JL. Complex transcriptional regulation by glucocorticoids and corticotropin-releasing hormone of proopiomelanocortin gene expression in rat pituitary cultures. DNA 1987; 6:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/76\">",
"      Luo X, Kiss A, Rabadan-Diehl C, Aguilera G. Regulation of hypothalamic and pituitary corticotropin-releasing hormone receptor messenger ribonucleic acid by adrenalectomy and glucocorticoids. Endocrinology 1995; 136:3877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/77\">",
"      Robinson BG, Emanuel RL, Frim DM, Majzoub JA. Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta. Proc Natl Acad Sci U S A 1988; 85:5244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/78\">",
"      Muglia LJ, Bethin KE, Jacobson L, et al. Pituitary-adrenal axis regulation in CRH-deficient mice. Endocr Res 2000; 26:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/79\">",
"      Cherradi N, Capponi AM, Gaillard RC, Pralong FP. Decreased expression of steroidogenic acute regulatory protein: a novel mechanism participating in the leptin-induced inhibition of glucocorticoid biosynthesis. Endocrinology 2001; 142:3302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/80\">",
"      Orth DN, Jackson RV, DeCherney GS, et al. Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol. J Clin Invest 1983; 71:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/81\">",
"      Trainer PJ, Faria M, Newell-Price J, et al. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab 1995; 80:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/82\">",
"      Conaglen JV, Donald RA, Espiner EA, et al. The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man. J Clin Endocrinol Metab 1984; 58:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/83\">",
"      Pavlov EP, Harman SM, Chrousos GP, et al. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986; 62:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/84\">",
"      Sheldon WR Jr, DeBold CR, Evans WS, et al. Rapid sequential intravenous administration of four hypothalamic releasing hormones as a combined anterior pituitary function test in normal subjects. J Clin Endocrinol Metab 1985; 60:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/85\">",
"      Ross JL, Schulte HM, Gallucci WT, et al. Ovine corticotropin-releasing hormone stimulation test in normal children. J Clin Endocrinol Metab 1986; 62:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/86\">",
"      Gallucci WT, Baum A, Laue L, et al. Sex differences in sensitivity of the hypothalamic-pituitary-adrenal axis. Health Psychol 1993; 12:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/87\">",
"      Kopelman PG, Grossman A, Lavender P, et al. The cortisol response to corticotrophin-releasing factor is blunted in obesity. Clin Endocrinol (Oxf) 1988; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/88\">",
"      Yanovski JA, Yanovski SZ, Friedman TC, et al. Etiology of the differences in corticotropin-releasing hormone-induced adrenocorticotropin secretion of black and white women. J Clin Endocrinol Metab 1996; 81:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/89\">",
"      DeCherney GS, DeBold CR, Jackson RV, et al. Diurnal variation in the response of plasma adrenocorticotropin and cortisol to intravenous ovine corticotropin-releasing hormone. J Clin Endocrinol Metab 1985; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/90\">",
"      Vale W, Vaughan J, Smith M, et al. Effects of synthetic ovine corticotropin-releasing factor, glucocorticoids, catecholamines, neurohypophysial peptides, and other substances on cultured corticotropic cells. Endocrinology 1983; 113:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/91\">",
"      Debold CR, Jackson RV, Kamilaris TC, et al. Effects of ovine corticotropin-releasing hormone on adrenocorticotropin secretion in the absence of glucocorticoid feedback inhibition in man. J Clin Endocrinol Metab 1989; 68:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/92\">",
"      Munemura M, Eskay RL, Kebabian JW. Release of alpha-melanocyte-stimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland: involvement of catecholamines and adenosine 3',5'-monophosphate. Endocrinology 1980; 106:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/93\">",
"      Tomiko SA, Taraskevich PS, Douglas WW. GABA acts directly on cells of pituitary pars intermedia to alter hormone output. Nature 1983; 301:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/94\">",
"      Shiver T, Familari M, Aguilera G. Regulation of intermediate pituitary corticotropin-releasing hormone receptors by dopamine. Endocrinology 1992; 130:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/95\">",
"      Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 1995; 92:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/96\">",
"      Potter E, Behan DP, Linton EA, et al. The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci U S A 1992; 89:4192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/97\">",
"      Woods RJ, David J, Baigent S, et al. Elevated levels of corticotrophin-releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid. Br J Rheumatol 1996; 35:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/98\">",
"      Kostich WA, Chen A, Sperle K, Largent BL. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 1998; 12:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/99\">",
"      Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006; 5:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/100\">",
"      Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001; 86:3787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/101\">",
"      Vgontzas AN, Bixler EO, Wittman AM, et al. Middle-aged men show higher sensitivity of sleep to the arousing effects of corticotropin-releasing hormone than young men: clinical implications. J Clin Endocrinol Metab 2001; 86:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/102\">",
"      Hermus AR, Pieters GF, Willemsen JJ, et al. Hypotensive effects of ovine and human corticotrophin-releasing factors in man. Eur J Clin Pharmacol 1987; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/103\">",
"      Oppermann D, Huber I, Nink M, Schulz V. Human corticotropin-releasing hormone in man: dose-response of minute ventilation and end-tidal partial pressures of carbon dioxide and oxygen. J Clin Endocrinol Metab 1987; 64:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/104\">",
"      Brown MR, Fisher LA, Spiess J, et al. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 1982; 111:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/105\">",
"      Lenz HJ, Hester SE, Brown MR. Corticotropin-releasing factor. Mechanisms to inhibit gastric acid secretion in conscious dogs. J Clin Invest 1985; 75:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/106\">",
"      Sutton RE, Koob GF, Le Moal M, et al. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982; 297:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/107\">",
"      Sirinathsinghji DJ, Rees LH, Rivier J, Vale W. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature 1983; 305:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/108\">",
"      Petraglia F, Sutton S, Vale W, Plotsky P. Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 1987; 120:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/109\">",
"      Dufau ML, Ulisse S, Khanum A, et al. LH action in the Leydig cell: modulation by angiotensin II and corticotropin releasing hormone, and regulation of P450(17) alpha mRNA. J Steroid Biochem 1989; 34:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/110\">",
"      Smith R, Mesiano S, Chan EC, et al. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. J Clin Endocrinol Metab 1998; 83:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/111\">",
"      Sirianni R, Mayhew BA, Carr BR, et al. Corticotropin-releasing hormone (CRH) and urocortin act through type 1 CRH receptors to stimulate dehydroepiandrosterone sulfate production in human fetal adrenal cells. J Clin Endocrinol Metab 2005; 90:5393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/112\">",
"      Challis JR, Matthews SG, Van Meir C, Ramirez MM. Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Placenta 1995; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/113\">",
"      Chan EC, Falconer J, Madsen G, et al. A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep. Endocrinology 1998; 139:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/114\">",
"      Baigent SM. Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 2001; 22:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/115\">",
"      Jessop DS, Harbuz MS, Lightman SL. CRH in chronic inflammatory stress. Peptides 2001; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/116\">",
"      Radulovic M, Spiess J. Immunomodulatory role of the corticotropin-releasing factor. Arch Immunol Ther Exp (Warsz) 2001; 49:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/117\">",
"      McEvoy AN, Bresnihan B, Fitzgerald O, Murphy EP. Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathway. Ann N Y Acad Sci 2002; 966:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/118\">",
"      Chatzaki E, Charalampopoulos I, Leontidis C, et al. Urocortin in human gastric mucosa: relationship to inflammatory activity. J Clin Endocrinol Metab 2003; 88:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/119\">",
"      Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 2004; 145:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/120\">",
"      Parkes DG, Weisinger RS, May CN. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001; 22:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/121\">",
"      Slominski A, Zbytek B, Semak I, et al. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 2005; 162:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6857/abstract/122\">",
"      Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A 2002; 99:7148.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 132 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6ABA7822FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6857=[""].join("\n");
var outline_f6_44_6857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYNTHESIS AND DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CRH IN PLASMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Binding protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REGULATION OF CRH SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTS ON PITUITARY HORMONE SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anterior lobe ACTH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intermediate lobe POMC peptide secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXTRAPITUITARY EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/132|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/57/24478\" title=\"figure 1\">",
"      CRH family neuropeptides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_44_6858="Regulation of myelopoiesis";
var content_f6_44_6858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Regulation of myelopoiesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/44/6858/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/44/6858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production of granulocytes and monocytes is a tightly regulated process. During steady state hematopoiesis, approximately 10",
"    <sup>",
"     8",
"    </sup>",
"    to 10",
"    <sup>",
"     9",
"    </sup>",
"    of these cells are produced per hour in the bone marrow to maintain their circulating numbers within fairly narrow limits. Production can be rapidly increased in the setting of infection or inflammation. The terms leukocytes and granulocytes are often used interchangeably, although they are somewhat different. The term leukocyte comprises granulocytes, monocytes, and lymphocytes, while the term granulocyte includes polymorphonuclear neutrophils, eosinophils, and basophils.",
"   </p>",
"   <p>",
"    Myelopoiesis begins with the differentiation of a small pool of pluripotent stem cells into the most primitive myeloid progenitors. These progenitors develop into recognizable myeloid precursors, which subsequently follow a specific differentiation program that culminates in the emergence of mature neutrophils, eosinophils, basophils and monocytes (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). This process is most likely driven by expression of successive combinations of transcription factors that in turn dictate the expression of adhesion and hematopoietic growth factor receptors (HGFRs):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adhesion receptors play an important role in the localization and release of maturing cells from specific niches in the bone marrow.",
"     </li>",
"     <li>",
"      Hematopoietic growth factors (HGFs), such as stem cell factor (SCF, also called Steel factor or c-kit ligand), interleukin (IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) are important for the amplification of progenitor cells, and bind to their target cells through specific receptors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    G-CSF is essential for the amplification and terminal differentiation of neutrophil progenitors and precursors, while macrophage colony-stimulating factor (M-CSF, CSF1) and IL-5 are lineage specific factors for the monocyte and eosinophil lineages, respectively.",
"   </p>",
"   <p>",
"    This topic will review the elements that underlie granulopoiesis and monopoiesis. A general discussion of hematopoiesis and stem cell function and issues related to neutrophil development and kinetics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF MYELOPOIESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Granulocyte and macrophage colony-forming cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first colony assays relevant to the study of the production of granulocytes and monocytes in the mouse were described in 1965 and 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Analogous assays were then developed for the human system [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/3\">",
"     3",
"    </a>",
"    ]. These studies demonstrated that individual cells derived from mouse spleen or bone marrow could give rise to colonies of up to several thousand differentiated granulocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macrophages in a soft agar medium. A period of 7 to 8 days was required for full maturation of these colonies in the mouse compared with 12 to 14 days in humans.",
"   </p>",
"   <p>",
"    Appropriate studies were performed to demonstrate the single cell origin of the colonies. These studies also demonstrated that a single progenitor cell, which was termed the colony-forming unit in culture, or CFU-C, was capable of differentiation into both granulocytes and macrophages, thus the designation CFU-GM. Unit gravity sedimentation and other separation methods have been used to demonstrate that CFU-GM represent a cell population distinguishable from the pluripotent stem cell [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A more restricted myeloid stem cell is referred to as CFU-GEMM because it is the precursor to lineage-specific stem cells for granulocytes, erythrocytes, monocytes, and megakaryocytes (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CFU-GEMM can be identified by markers for CD34 and HLA-DR. Some human myeloid stem cells express an additional marker for CD64 which identifies a specific stem cell dedicated to granulocyte and monocyte development. This CD34, HLA-DR, and CD-64 positive stem cell is called CFU-GM because colonies of mature granulocytes and",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    form when the stem cell is cultured in semisolid medium with appropriate growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The major growth factors required for maturing CFU-GEMM into CFU-GM are stem cell factor (SCF), interleukin (IL)-3, IL-6 (induced by IL-3), flt3 ligand, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). GM-CSF receptor expression begins in immature precursor cells and is progressively increased during differentiation into mature granulocytes and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term liquid bone marrow cultures have been particularly helpful in defining humoral and cell-cell interactions that induce myeloid differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/10\">",
"     10",
"    </a>",
"    ]. CFU-GM give rise to the more mature granulocyte and macrophage colony-forming units, CFU-G and CFU-M, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, CFU-GM can be distinguished from the eosinophil and basophil progenitors, CFU-Eo and CFU-Baso, each arising independently from the myeloid stem cell (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). It is now accepted that CFU-GM, under the influence of SF, IL-3, GM-CSF, G-CSF,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    M-CSF ultimately gives rise to mature phagocytes, the granulocytes and monocytes.",
"   </p>",
"   <p>",
"    Although a clonogenic assay of granulocyte progenitors was developed almost a decade before the erythroid clonogenic assay, the various factors responsible for granulocyte and monocyte-macrophage development remain incompletely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neutrophil production",
"    </span>",
"    &nbsp;&mdash;&nbsp;A model that describes the production and kinetics of human neutrophils suggests that it is highly compartmentalized. The relatively tiny peripheral blood pool is divided into two components in equilibrium: the circulating granulocyte pool and the marginating granulocyte pool. These pools provide entrance into the tissues.",
"   </p>",
"   <p>",
"    The level of circulating cells is buffered by an immense marrow reserve of identifiable precursors, some of which are in the mitotic compartment (myeloblasts, promyelocytes, and myelocytes) and others in a maturing postmitotic storage compartment (metamyelocytes, band, and mature neutrophilic forms) (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ). The transit times within each compartment are relatively long, so that a huge reserve remains available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The kinetics of proliferation of recognizable cell precursors have been evaluated using labeled precursors of DNA. These studies indicate that the maturation time for neutrophils from the myeloblast stage is about eight days (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ). The so-called labeling indices from which measurements of cell cycle times can be made have served as important approaches to the study of the pharmacology and toxicity of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Release of neutrophils into the blood compartment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final stage of granulocyte production, their release from the marrow, is also multifaceted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/11\">",
"     11",
"    </a>",
"    ]. At least four factors may influence granulocyte egress:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organization and localization of the cells in relation to vascular channels",
"     </li>",
"     <li>",
"      The development of nuclear and cytoplasmic changes that increase cell deformability",
"     </li>",
"     <li>",
"      Factors such as chemokines, cytokines, microbial products, and other inflammatory mediators [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link&amp;anchor=H21#H21\">",
"       \"Causes of neutrophilia\", section on 'Effect of proinflammatory cytokines'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=see_link&amp;anchor=H10#H10\">",
"       \"Definition and mechanisms of leukocytosis and neutrophilia\", section on 'Regulation of neutrophil counts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The regulation of blood flow through vascular channels in the marrow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neutrophils, which appear to reside in the blood for a mean time of about 10 hours (half-time of 6.7 hours), must leave the bloodstream and localize to sites of inflammation. They interact with the endothelial cells that line blood vessels through a family of integrin receptors that include LFA-1 (CD11a), Mo-1 or Mac-1 (CD11b), and",
"    <span class=\"nowrap\">",
"     gp150/95",
"    </span>",
"    (CD11c). All three receptors share a common beta subunit, CD18 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/13\">",
"     13",
"    </a>",
"    ], which is mutated in the autosomal recessive disease leukocyte adhesion deficiency (LAD). These patients have a total or partial absence of the dimeric complexes from the surface of neutrophils. As a result neutrophils cannot leave the circulation, and patients suffer from pyogenic infection but have a neutrophil and monocyte leukocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary disorders of phagocytic function: An overview\", section on 'Leukocyte adhesion deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms controlling the release of PMNs from the bone marrow are only partially understood. A variety of compounds induce PMN movement into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, and certain androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. To successfully emerge into the circulation, PMNs must deform and migrate to the luminal side of the endothelial sinusoidal surface. Endotoxin affects the relationship between marrow sinus endothelial cells and the stromal macrophages covering nonluminal sinusoidal surfaces; it induces retraction of macrophages away from the endothelium which facilitates contact between PMNs and endothelial cells and allows PMN egress from the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro, PMNs and bands readily pass through millipore filters with pore sizes of 1 micron in response to chemoattractants. Metamyelocytes and late myelocytes are impaired in these responses, whereas early myelocytes, promyelocytes and myeloblasts cannot move or deform [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. Blood viscosity at high flow rates is a function of cell deformability and volume. As a result, viscosity increases dramatically in patients with acute leukemia and markedly increased numbers of circulating blast forms, with leukocrits above 20 percent or total white cell counts above",
"    <span class=\"nowrap\">",
"     400,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/22\">",
"     22",
"    </a>",
"    ]. This problem does not occur when similar total white cell counts are due to the presence of neutrophils rather than blasts.",
"   </p>",
"   <p>",
"    In rabbits, infusion of C5a or TNF-alpha induces leukocytosis, which is not prevented when the principal adhesion proteins of PMNs, beta-2 integrin and L-selectin are blocked by specific antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/17\">",
"     17",
"    </a>",
"    ]. This observation suggests that PMN egress from the bone marrow is mediated by interactions different from those governing chemotaxis and diapedesis as described below (",
"    <a class=\"graphic graphic_figure graphicRef60528 \" href=\"UTD.htm?42/23/43376\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    G-CSF is the principal cytokine that stimulates not only the production of neutrophils but also their release from the bone marrow. While the mechanism of G-CSF-mediated release is not completely understood, SDF-1, a stromal cell derived factor, and its ligand CXCR4, expressed on many hematopoietic cells including neutrophils, may play a key role. The",
"    <span class=\"nowrap\">",
"     SDF-1/CXCR4",
"    </span>",
"    interaction appears to retain neutrophils within the bone marrow. G-CSF administration leads to a reduction in SDF-1 expression as well as CXCR4 cleavage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mouse models have demonstrated a G-CSF-dependent feedback loop that ensures neutrophil production, both in response to infection and in the steady state [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/25\">",
"     25",
"    </a>",
"    ]. In both cases, in this model G-CSF production is increased in a Toll-like receptor (TLR)-dependent mechanism. The bacterial cell wall component LPS is abundant during systemic infection; in the steady state LPS may be supplied by commensal bacteria in the gut. LPS binds to TLR4, most likely expressed on stromal bone marrow cells, causing them to produce G-CSF. G-CSF in turn stimulates granulopoiesis and release of mature neutrophils into the circulation; this is achieved by disruption of ligand-receptor interactions through reductions in CXCR4 on the neutrophil surface and",
"    <span class=\"nowrap\">",
"     CXCL12/SDF-1",
"    </span>",
"    in the bone marrow stroma. Interestingly, TLRs are also expressed on hematopoietic stem and progenitor cells, and TLR ligands, such as bacterial LPS, can induce self-renewal in HSCs and bias commitment to myeloid or lymphoid lineages. As an example, acute infection with Pseudomonas aeruginosa can lead to neutropenia by TLR4 mediated inhibition of myeloid transcription factors PU.1 and",
"    <span class=\"nowrap\">",
"     c/EBPalpha,",
"    </span>",
"    while chronic infection with P. aeruginosa can increase neutrophils at the expense of a reduction in lymphopoiesis by reducing levels of a lymphoid transcription factor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocytes irreversibly leave the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] and differentiate further into fixed-tissue macrophages, a category comprising the alveolar macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/32\">",
"     32",
"    </a>",
"    ], hepatic Kupffer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/33\">",
"     33",
"    </a>",
"    ], dermal Langerhans' cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/34\">",
"     34",
"    </a>",
"    ], osteoclasts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/35\">",
"     35",
"    </a>",
"    ], peritoneal and pleural macrophages, and perhaps brain microglial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REGULATION OF MYELOPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enormous diversity of the myeloid system, the high turnover rate of granulocytes, and the necessity to maintain splenic, marginated, and bone marrow granulocyte pools in order to meet sudden demands caused by infection has led to the evolution of an extremely complex regulatory network. Many of the factors that allow release of granulocytes from storage pools are distinct from CSFs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, GM-CSF can inhibit granulocyte motility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/37\">",
"     37",
"    </a>",
"    ] and can activate granulocytes to increase superoxide anion generation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This complexity in vivo does not permit studies analogous to those in which erythropoiesis is influenced by hypertransfusion or hemorrhage and megakaryocytopoiesis is stimulated by induced thrombocytopenia. Thus, investigators have relied heavily upon in vitro progenitor assays to study the regulation of myelopoiesis. Both transcription factors and growth factors play an important role in this process and their individual effects have been determined in part by the generation of mice lacking genes for specific proteins (",
"    <a class=\"graphic graphic_table graphicRef67668 \" href=\"UTD.htm?16/30/16876\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transcription factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloid transcription factors play a major role in regulating the expression of myeloid specific genes and are therefore important for commitment to the myeloid lineage and for normal myeloid differentiation. Whether the transcription factors themselves are regulated by environmental or intrinsic signals is still a major unanswered question. It appears that, once induced, their transcription can often be amplified by autoregulatory loops, and that the factors frequently act in subtle combinatorial mechanisms to induce different myeloid genes (",
"    <a class=\"graphic graphic_figure graphicRef71394 \" href=\"UTD.htm?28/60/29647\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occupancy of regulatory regions of lineage-specific genes also depends on chromatin configuration and methylation status. There is evidence that during myelopoiesis these epigenetic changes occur in a step-wise manner; in primitive cells lysozyme gene regulatory sites are transiently occupied, whereas in mature macrophages much more stable occupancy is attained at the time that the gene becomes maximally expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PU.1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PU.1 (Spi-1) transcription factor is a member of the Ets family and is expressed principally in",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    and B lymphocytes, and also in erythroid cells and granulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Potential target genes include the integrin CD11b, M-CSF receptor, GM-CSF receptor alpha, G-CSF receptor, and the Igl light chain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Mice that lack PU.1 die in utero with absence of monocytes, granulocytes, and T and B lymphocytes; anemia is variable and therefore does not explain the prenatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/49\">",
"     49",
"    </a>",
"    ]. On the other hand, mice with severely reduced expression of PU.1 (ie, PU.1 knockdown mice) develop acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/50,51\">",
"     50,51",
"    </a>",
"    ] and heterozygous deletion of the PU.1 locus has been associated with acute myeloid leukemia in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     C/EBP family",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     CCAAT/enhancer",
"    </span>",
"    binding protein",
"    <span class=\"nowrap\">",
"     (C/EBP)",
"    </span>",
"    family of transcription factors bind to DNA through a basic region-leucine zipper domain (bZIP). There are several family members",
"    <span class=\"nowrap\">",
"     (C/EBP-alpha,",
"    </span>",
"    <span class=\"nowrap\">",
"     C/EBP-beta",
"    </span>",
"    (NF-IL-6),",
"    <span class=\"nowrap\">",
"     C/EBP-gamma,",
"    </span>",
"    <span class=\"nowrap\">",
"     C/EBP-delta",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon)",
"    </span>",
"    that are differentially expressed during myelopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/53\">",
"     53",
"    </a>",
"    ]. During maturation of a myeloid precursor cell line to terminally differentiated granulocytes, there was an increase",
"    <span class=\"nowrap\">",
"     (C/EBP-beta",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon),",
"    </span>",
"    or an increase followed by either a partial",
"    <span class=\"nowrap\">",
"     (C/EBP-delta)",
"    </span>",
"    or marked",
"    <span class=\"nowrap\">",
"     (C/EBP-alpha)",
"    </span>",
"    reduction in the level of expression of members of this family [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In one study of 408 patient samples and 5 cell lines representing 11 different malignancies, mutation of",
"    <span class=\"nowrap\">",
"     C/EBP-alpha",
"    </span>",
"    was noted in acute myeloid leukemia and myelodysplasia, but rarely in other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functions of the different members of",
"    <span class=\"nowrap\">",
"     C/EBP",
"    </span>",
"    family have been delineated by target disruption of specific genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       C/EBP-alpha",
"      </span>",
"      has been implicated in the regulation of hepatocyte, adipocyte, and myeloid differentiation (levels are low in undifferentiated dividing cells but high in quiescent terminally differentiated cells), and also in myeloid CSF receptor promoter function [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       C/EBP-alpha",
"      </span>",
"      deficient mice die within the first few hours after birth from impaired glucose metabolism; they also have a selective block in granulocyte production leading to the absence of mature granulocytes and a profound and selective reduction in G-CSF receptor mRNA expression and in CFU-G [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice that lack",
"      <span class=\"nowrap\">",
"       C/EBP-beta",
"      </span>",
"      produce monocytes that are defective in bactericidal and tumoricidal function; in addition, their macrophages and fibroblasts, but not their endothelial cells, fail to produce G-CSF in response to lipopolysaccharide (LPS) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/60\">",
"       60",
"      </a>",
"      ]. In another study,",
"      <span class=\"nowrap\">",
"       C/EBP-beta",
"      </span>",
"      deficient mice had an increase in IL-6 production and enhanced proliferation of a number of hematopoietic lineages, a syndrome that resembles Castleman's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice with null mutations of the",
"      <span class=\"nowrap\">",
"       C/EBP-epsilon",
"      </span>",
"      gene develop normally but die from opportunistic infections at three to five months of age because of functional abnormalities of neutrophils and eosinophils [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/62\">",
"       62",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       C/EBP-epsilon-null",
"      </span>",
"      neutrophils fail to develop specific granules or their content proteins, and have defects in chemotaxis, respiratory burst generation, and phagocytosis. These observations led to the demonstration that patients with specific granule deficiency, a rare disorder of neutrophil function associated with increased infections, was caused by mutations in the gene encoding",
"      <span class=\"nowrap\">",
"       C/EBP-epsilon.",
"      </span>",
"      The mice also develop a terminal myelodysplasia with proliferation of atypical granulocytes, although it was not clear whether this was truly a clonal disorder or a response to chronic infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Core binding factor family",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core binding factor (CBF) family is another group of transcription factors that plays an important role in the regulation of myeloid specific promoters such as those for the myeloperoxidase (MPO) and neutrophil elastase (NE) genes. These were first identified on the basis of their ability to bind to the polyomavirus enhancer-binding protein",
"    <span class=\"nowrap\">",
"     2/core",
"    </span>",
"    binding factor",
"    <span class=\"nowrap\">",
"     (PEBP2/CBF).",
"    </span>",
"    Two alpha subunits (CBF-alpha-1 and CBF-alpha-2, also known as AML1 or RUNX1) bind DNA with low affinity, but the affinity is strengthened in the presence of the non-DNA-binding beta subunit (CBF-beta). In addition, AML1 can act synergistically with",
"    <span class=\"nowrap\">",
"     C/EBP-alpha",
"    </span>",
"    to activate the M-CSF receptor promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mice lacking AML1 die in utero by day 12.5 due to hemorrhage and they fail to produce all definitive hematopoietic lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Similar defects have been observed in CBF-beta knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/65\">",
"     65",
"    </a>",
"    ]. It has been suggested that CBF-alpha-2 and CBF-beta are required for the emergence of definitive hematopoietic stem cells in the embryo; both genes are also required in the later stages of differentiation of some hematopoietic lineages (megakaryocytes, T and B cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two genes also play a role in leukemogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. AML1 is involved in one of the most frequent chromosome translocations in acute myeloid leukemia (M2 AML), t(8;21)(q22;q22), which results in the production of the",
"    <span class=\"nowrap\">",
"     AML/ETO",
"    </span>",
"    fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/68-72\">",
"     68-72",
"    </a>",
"    ], while CBF-beta is involved in a chromosome inversion inv(16)(p13;q22) that is associated with eosinophilic AML (M4eo AML) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/73\">",
"     73",
"    </a>",
"    ]. The abnormal",
"    <span class=\"nowrap\">",
"     AML/ETO",
"    </span>",
"    protein can act as a dominant negative inhibitor of AML1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. However, murine knock-in studies suggest that the mechanism may be more complex. Mice heterozygous for AML1-ETO have a severe block in hematopoiesis but yolk sac cells generate CFU-M whereas yolk sac cells from AML1 or CBF-beta knockout mice contain no colony-forming cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experiments in mice have demonstrated that AML1 binds to functionally important sites within the PU.1 upstream regulatory element and regulates PU.1 expression at both embryonic and adult stages of development [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'PU.1'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional evidence for the importance of AML1 in myelopoiesis comes from an understanding of the condition \"familial platelet disorder with predisposition to myelodysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute myeloid leukemia",
"    <span class=\"nowrap\">",
"     (FPD/AML)\".",
"    </span>",
"    This is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, a decrement in megakaryocyte colony formation, and an approximately 37 percent incidence of acute myeloid leukemia (AML). Nonsense mutations or intragenic deletion of AML1 have been seen in this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25882?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Familial platelet disorder with predisposition to AML'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Retinoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoic acid (RA) may play a direct role in myelopoiesis as evidenced by the following observations: vitamin A deficiency is associated with defective hematopoiesis; RA can induce myeloid differentiation in cell lines and in primary leukemic cells; and all-trans retinoic acid is often effective in the treatment of acute promyelocytic leukemia (APML). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The leukemic cells of almost all patients with APL have a balanced (15;17) translocation involving the PML gene on chromosome 15 and the retinoic acid receptor-alpha (RAR-alpha) gene on chromosome 17. The PML-RARalpha fusion protein associated with this translocation in APML is an abnormal retinoic acid receptor with altered DNA binding and transcriptional activities, thereby preventing differentiation of promyelocytes. A similar effect, blocked differentiation at the promyelocyte stage, can be induced by expression of a dominant negative RAR in a multipotent murine hematopoietic cell line and in normal mouse bone marrow cells; this effect can be overcome by high concentrations of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of growth factors also play a major role in myelopoiesis, including IL-3, GM-CSF, G-CSF, and M-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Effects on progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been made in murine and human studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Murine IL-3 stimulates a broad spectrum of myeloid progenitor cells including CFU-GM, CFU-G, CFU-M, CFU-Eo, erythroid burst-forming units (BFU-E), megakaryocyte CFU (CFU-Meg) and mast cells.",
"     </li>",
"     <li>",
"      As its name implies, GM-CSF was initially thought to provide a more restricted stimulus to the proliferation and development of CFU-GM. However, murine studies with purified or recombinant GM-CSF have shown that it also stimulates the initial proliferation of other progenitors such as BFU-E [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/81,82\">",
"       81,82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The other murine factors, G-CSF and M-CSF are more restricted and predominantly stimulate granulocyte and monocyte colony forming units (CFU-G and CFU-M), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. However, combinations of Stem Cell Factor (SCF) and G-CSF enhance progenitor cells of multiple lineages in blast colonies, indicating a broader action on primitive progenitor cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of G-CSF as a myelopoietic growth factor was revealed in mice with deletion of the G-CSF gene [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/86\">",
"     86",
"    </a>",
"    ]. These mice have a chronic neutropenia (20 percent to 30 percent of normal levels) and reduced bone marrow myeloid precursors and progenitors. They also have a markedly impaired capacity to increase neutrophil and monocyte counts after infection with Listeria monocytogenes.",
"   </p>",
"   <p>",
"    With the possible exception of GM-CSF, the activities of the human CSFs are similar to those of the corresponding murine factors. Both IL-3 and GM-CSF affect a similar broad spectrum of human progenitor cells including CFU-GEMM, CFU-GM, CFU-G, CFU-M, CFU-Eo and CFU-Meg (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effects on mature cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their effects on progenitor differentiation, the colony-stimulating factors also induce a variety of functional changes in mature cells. As an example, GM-CSF inhibits polymorphonuclear neutrophil migration under agarose [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/87\">",
"     87",
"    </a>",
"    ], induces antibody dependent cytotoxicity (ADCC) for human target cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/37\">",
"     37",
"    </a>",
"    ], and increases neutrophil phagocytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the functional changes in mature cells may be related to a GM-CSF-induced increase in cell surface expression of a family of antigens that function as cell adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/88\">",
"     88",
"    </a>",
"    ]. The increase in antigen expression is rapid and is associated with increased aggregation of neutrophils; both are maximal at the migration inhibitory concentration of 500",
"    <span class=\"nowrap\">",
"     pmol/L,",
"    </span>",
"    and granulocyte-granulocyte adhesion can be inhibited by an antigen-specific monoclonal antibody. GM-CSF also acts as a potent stimulus of eosinophil ADCC, superoxide production, and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G-CSF and M-CSF also affect mature cells. G-CSF acts as a potent stimulus of neutrophil superoxide production, chemotaxis, ADCC, and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], while M-CSF activates mature macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/92\">",
"     92",
"    </a>",
"    ] and enhances macrophage cytotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insight into the in vivo role of GM-CSF comes from studies in mice that carried two null alleles of the GM-CSF gene [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. These mice had normal basal hematopoiesis, but developed progressive accumulation of surfactant lipids and proteins in the alveolar space, the defining characteristic of idiopathic human pulmonary alveolar proteinosis. Extensive lymphoid hyperplasia associated with lung airways and blood vessels was also found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surfactant proteins and lipids are synthesized by type II pneumocytes and cleared from the alveolar space by type II cells and by alveolar macrophages. The lungs from the null animals showed normal surfactant synthetic capacity and no accumulation in type II pneumocytes. In contrast, the alveolar macrophages showed a marked increase in surfactant protein and lipid, suggesting strongly that these cells cannot process surfactant in the absence of GM-CSF.",
"   </p>",
"   <p>",
"    Similar pulmonary pathology is seen in mice with null mutations of the common chain of the",
"    <span class=\"nowrap\">",
"     GM-CSF/IL-3/IL-5",
"    </span>",
"    receptor (beta c) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/86,95\">",
"     86,95",
"    </a>",
"    ]. These mice also have low basal numbers of eosinophils and absence of blood and lung eosinophilia in response to infection with the parasite Nippostrongylus brasiliensis.",
"   </p>",
"   <p>",
"    Human pulmonary alveolar proteinosis (PAP) is now known to be due to autoantibodies to GM-CSF in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/96\">",
"     96",
"    </a>",
"    ], while a small number of patients have mutations in the alpha chain of the GM-CSF receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/97,98\">",
"     97,98",
"    </a>",
"    ] or the common beta chain of the",
"    <span class=\"nowrap\">",
"     IL-3/GM-CSF/IL-5",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stem cell factor and flt3 ligand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cell factor (SCF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/100,101\">",
"     100,101",
"    </a>",
"    ] and the flt3 ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/102-104\">",
"     102-104",
"    </a>",
"    ], both receptor tyrosine kinase ligands, interact with a variety of hematopoietic progenitor cells, perhaps most importantly with very early stem cell populations (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). SCF also plays an important role in melanocyte growth and development, which is reflected in the coat color effects of mutations in SCF or its receptor, Kit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mice defective in either SCF (Sl mice) or Kit (W mice) have serious hematopoietic defects including macrocytic anemia, mast cell deficiencies, and deficiencies in the stem cell compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/100\">",
"     100",
"    </a>",
"    ]. In vitro, the proliferative activity of SF with hematopoietic cells is minimal alone, largely yielding mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/105\">",
"     105",
"    </a>",
"    ] and is generally most evident when combined with other hematopoietic growth factors (HGFs) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/100\">",
"     100",
"    </a>",
"    ]. It is particularly effective when combined with HGFs such as IL-3, IL-1 or IL-11 in promoting the expansion of \"blast\" like cells that retain considerable potential for yielding multilineage colonies in secondary culture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/106-108\">",
"     106-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The flt3 receptor tyrosine kinase was originally identified as a novel receptor present in hematopoietic stem cells; in human marrow, its expression is largely limited to the CD34+ cell population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. Flt3 ligand alone yields low numbers of CFU-GM colonies from human bone marrow but acts synergistically with other cytokines including IL-3, GM-CSF, erythropoietin, and SCF to yield enhanced colony formation, both in terms of size and numbers of colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/103,112,113\">",
"     103,112,113",
"    </a>",
"    ]. The synergy observed between flt3 ligand and the other HGFs is comparable to that observed with SCF in similar systems with the exception that flt3 ligand has little effect on BFU-E [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Homeobox genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The homeobox genes of the HOXA and HOXB gene clusters are expressed in primitive blood cells and also seem to play a role in blood cell differentiation. Disruption of the HOXA9 gene in mice leads to a 30 to 40 percent reduction in leukocytes and a blunted PMN response to G-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     REGULATION OF HEMATOPOIETIC GROWTH FACTOR GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different cell types, including T lymphocytes,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    fibroblasts, epithelial cells, and endothelial cells elaborate various hematopoietic growth factors (HGFs), especially following stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/115-118\">",
"     115-118",
"    </a>",
"    ]. In addition, conditioned media from murine organ cultures of lung, muscle, thymus, bone shaft and heart all contain readily detectable levels of many different HGFs and cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of HGFs under steady-state conditions are very low, but elevate rapidly following systemic administration of agents such as lipopolysaccharide (ie, endotoxin) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/119\">",
"     119",
"    </a>",
"    ]. Thus, it seems likely that normal hematopoiesis is maintained by low level expression of HGFs locally in the microenvironment of the bone marrow, spleen and thymus while systemic circulation of HGFs becomes more important following infection, when inflammatory mediators such as IL-1 and TNF-alpha can act as potent stimulators of HGF production by many cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. Because HGF production is closely regulated in most cell types, it may be that binding of hematopoietic cells to stromal cells also activates stromal HGF production, analogous to the induction of IL-6 expression by binding of myeloma cells to stromal fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of HGF gene expression by various stimuli has been reported for many different cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/115-118\">",
"     115-118",
"    </a>",
"    ]. This activation serves to accelerate blood cell production in times of stress such as in response to infection, marrow damage, or severe bleeding. Among the many types of HGF-producing cells, the most prominent include T and B lymphocytes,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    and mesodermal cells including fibroblasts, endothelial cells, and epithelial cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of some of the HGF genes, notably IL-3 and IL-5, is restricted largely to activated T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/124-126\">",
"       124-126",
"      </a>",
"      ]. Activated T cells also produce GM-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/127\">",
"       127",
"      </a>",
"      ], M-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/128\">",
"       128",
"      </a>",
"      ], and IL-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/129\">",
"       129",
"      </a>",
"      ] but these HGFs are produced by many other cells as well, including monocytes, macrophages, and the various mesodermally derived cells.",
"     </li>",
"     <li>",
"      G-CSF is expressed by",
"      <span class=\"nowrap\">",
"       monocytes/macrophages",
"      </span>",
"      and the various mesodermally derived cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/118\">",
"       118",
"      </a>",
"      ], while the expression of IL-11 is even further restricted, as it does not appear to be made by T cells nor by",
"      <span class=\"nowrap\">",
"       monocyte/macrophages",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/130-132\">",
"       130-132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SF and flt3 ligand are broadly expressed in many mesodermal cell types [",
"      <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/100,103,112\">",
"       100,103,112",
"      </a>",
"      ] but thus far, little is known about the regulation of their expression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expression of the HGFs and other cytokines is often triggered in cells by exposure to other cytokines or growth factors, leading to the concept that there are complicated interacting networks of cytokines that serve to control and coordinate many physiologic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/44/6858/abstract/133,134\">",
"     133,134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1305306\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myelopoiesis begins with the differentiation of pluripotent stem cells into the most primitive myeloid progenitors. These progenitors develop into myeloid precursors, which follow specific differentiation programs culminating in the emergence of mature neutrophils, eosinophils, basophils and monocytes (",
"      <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"       \"Normal neutrophil development and kinetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maturation of pluripotent stem cells is controlled by expression of successive combinations of transcription factors that in turn dictate the expression of adhesion and hematopoietic growth factor receptors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Regulation of myelopoiesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most prominent cells producing hematopoietic growth factors include T lymphocytes,",
"      <span class=\"nowrap\">",
"       monocytes/macrophages,",
"      </span>",
"      and other mesodermal cells, such as fibroblasts and endothelial cells. These factors serve to accelerate blood cell production in times of stress such as in response to infection, marrow damage, or severe bleeding. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Regulation of hematopoietic growth factor genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of compounds induce movement of mature neutrophils into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, G-CSF, and certain androgens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy of myelopoiesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/1\">",
"      Pluznik DH, Sachs L. The cloning of normal \"mast\" cells in tissue culture. J Cell Physiol 1965; 66:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/2\">",
"      Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/3\">",
"      Moore MA. Humoral regulation of granulopoiesis. Clin Haematol 1979; 8:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/4\">",
"      Haskill JS, Moore MA. Two dimensional cell separation: comparison of embryonic and adult haemopoietic stem cells. Nature 1970; 226:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/5\">",
"      Metcalf D. Detection and analysis of human granulocyte--monocyte precursors using semi-solid cultures. Clin Haematol 1979; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/6\">",
"      Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/7\">",
"      Olweus J, Lund-Johansen F, Terstappen LW. CD64/Fc gamma RI is a granulo-monocytic lineage marker on CD34+ hematopoietic progenitor cells. Blood 1995; 85:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/8\">",
"      Leary AG, Ogawa M, Strauss LC, Civin CI. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest 1984; 74:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/9\">",
"      Wognum AW, Westerman Y, Visser TP, Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood 1994; 84:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/10\">",
"      Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91:335.",
"     </a>",
"    </li>",
"    <li>",
"     Lichtman MA, Chamberlain JK, Weed RI, et al.. The regulation of the release of granulocytes from normal marrow. In: The Granulocyte: Function and Clinical Utilization, Greenwalt TJ, Jamieson GA (Eds), Alan R Liss, New York 1977. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/12\">",
"      Opdenakker G, Fibbe WE, Van Damme J. The molecular basis of leukocytosis. Immunol Today 1998; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/13\">",
"      Sanchez-Madrid F, Nagy JA, Robbins E, et al. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med 1983; 158:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/14\">",
"      Deinard AS, Page AR. A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood. Br J Haematol 1974; 28:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/15\">",
"      Ghebrehiwet B, M&uuml;ller-Eberhard HJ. C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 1979; 123:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/16\">",
"      Mitchell RH, McClelland RM, Kampschmidt RF. Comparison of neutrophilia induced by leukocytic endogenous mediator and by cobra venom factor. Proc Soc Exp Biol Med 1982; 169:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/17\">",
"      Jagels MA, Chambers JD, Arfors KE, Hugli TE. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood 1995; 85:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/18\">",
"      Vogel JM, Yankee RA, Kimball HR, et al. The effect of etiocholanolone on granulocyte kinetics. Blood 1967; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/19\">",
"      Lichtman MA, Weed RI. Alteration of the cell periphery during granulocyte maturation: relationship to cell function. Blood 1972; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/20\">",
"      Hirahata T, Bjorkman D, Chamberlain JK. Endotoxin: a twofold effect on bone marrow ultrastructure. Scanning Microsc 1987; 1:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/21\">",
"      Giordano GF, Lichtman MA. Marrow cell egress. The central interaction of barrier pore size and cell maturation. J Clin Invest 1973; 52:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/22\">",
"      Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982; 60:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/23\">",
"      Semerad CL, Liu F, Gregory AD, et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/24\">",
"      L&eacute;vesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/25\">",
"      Bugl S, Wirths S, Radsak MP, et al. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood 2013; 121:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/26\">",
"      Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/27\">",
"      Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011; 186:5367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/28\">",
"      Rodriguez S, Chora A, Goumnerov B, et al. Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood 2009; 114:4064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/29\">",
"      Boiko JR, Borghesi L. Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine 2012; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/30\">",
"      van Furth R, Raeburn JA, van Zwet TL. Characteristics of human mononuclear phagocytes. Blood 1979; 54:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/31\">",
"      Meuret G. Human monocytopoiesis. Exp Hematol 1974; 2:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/32\">",
"      Thomas ED, Ramberg RE, Sale GE, et al. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science 1976; 192:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/33\">",
"      Gale RP, Sparkes RS, Golde DW. Bone marrow origin of hepatic macrophages (Kupffer cells) in humans. Science 1978; 201:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/34\">",
"      Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/35\">",
"      Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. Nature 1980; 283:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/36\">",
"      Carr I. The biology of macrophages. Clin Invest Med 1978; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/37\">",
"      Gasson JC, Weisbart RH, Kaufman SE, et al. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 1984; 226:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/38\">",
"      Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 1985; 314:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/39\">",
"      Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/40\">",
"      Tagoh H, Melnik S, Lefevre P, et al. Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro. Blood 2004; 103:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/41\">",
"      Lefevre P, Lacroix C, Tagoh H, et al. Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene. J Biol Chem 2005; 280:27552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/42\">",
"      Goebl MK. The PU.1 transcription factor is the product of the putative oncogene Spi-1. Cell 1990; 61:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/43\">",
"      Klemsz MJ, McKercher SR, Celada A, et al. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990; 61:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/44\">",
"      Pahl HL, Scheibe RJ, Zhang DE, et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993; 268:5014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/45\">",
"      Pongubala JM, Van Beveren C, Nagulapalli S, et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993; 259:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/46\">",
"      Shin MK, Koshland ME. Ets-related protein PU.1 regulates expression of the immunoglobulin J-chain gene through a novel Ets-binding element. Genes Dev 1993; 7:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/47\">",
"      Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 1994; 14:8085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/48\">",
"      Hohaus S, Petrovick MS, Voso MT, et al. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 1995; 15:5830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/49\">",
"      Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/50\">",
"      Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/51\">",
"      Steidl U, Rosenbauer F, Verhaak RG, et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 2006; 38:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/52\">",
"      Bonadies N, Pabst T, Mueller BU. Heterozygous deletion of the PU.1 locus in human AML. Blood 2010; 115:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/53\">",
"      Wang QF, Friedman AD. CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 2002; 99:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/54\">",
"      Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992; 80:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/55\">",
"      Yamanaka R, Kim GD, Radomska HS, et al. CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci U S A 1997; 94:6462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/56\">",
"      Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/57\">",
"      Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 1996; 16:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/58\">",
"      Schepers H, Wierenga AT, van Gosliga D, et al. Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood 2007; 110:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/59\">",
"      Zhang DE, Zhang P, Wang ND, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 1997; 94:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/60\">",
"      Tanaka T, Akira S, Yoshida K, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 1995; 80:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/61\">",
"      Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J 1995; 14:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/62\">",
"      Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A 1997; 94:13187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/63\">",
"      Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/64\">",
"      Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996; 93:3444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/65\">",
"      Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996; 87:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/66\">",
"      Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/67\">",
"      Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/68\">",
"      Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/69\">",
"      Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 1991; 88:10431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/70\">",
"      Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13:6336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/71\">",
"      Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/72\">",
"      Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/73\">",
"      Liu P, Tarl&eacute; SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/74\">",
"      Takahashi A, Satake M, Yamaguchi-Iwai Y, et al. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 1995; 86:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/75\">",
"      Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995; 15:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/76\">",
"      Frank R, Zhang J, Uchida H, et al. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995; 11:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/77\">",
"      Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/78\">",
"      Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 2008; 40:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/79\">",
"      Tsai S, Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A 1993; 90:7153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/80\">",
"      Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/81\">",
"      Metcalf D, Johnson GR, Burgess AW. Direct stimulation by purified GM-CSF of the proliferation of multipotential and erythroid precursor cells. Blood 1980; 55:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/82\">",
"      Sieff CA, Emerson SG, Donahue RE, et al. Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science 1985; 230:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/83\">",
"      Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol 1983; 116:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/84\">",
"      Metcalf D, Stanley ER. Haematological effects in mice of partially purified colony stimulating factor (CSF) prepared from human urine. Br J Haematol 1971; 21:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/85\">",
"      Metcalf D. Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Natl Acad Sci U S A 1991; 88:11310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/86\">",
"      Hercus TR, Thomas D, Guthridge MA, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009; 114:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/87\">",
"      Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/88\">",
"      Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/89\">",
"      Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/90\">",
"      Lopez AF, To LB, Yang YC, et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A 1987; 84:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/91\">",
"      Lopez AF, Nicola NA, Burgess AW, et al. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. J Immunol 1983; 131:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/92\">",
"      Suzuki S, Kobayashi M, Chiba K, et al. Autocrine production of epithelial cell-derived neutrophil attractant-78 induced by granulocyte colony-stimulating factor in neutrophils. Blood 2002; 99:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/93\">",
"      Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/94\">",
"      Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91:5592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/95\">",
"      Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/96\">",
"      Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/97\">",
"      Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/98\">",
"      Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/99\">",
"      Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/100\">",
"      Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/101\">",
"      Kent D, Copley M, Benz C, et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res 2008; 14:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/102\">",
"      Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/103\">",
"      Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/104\">",
"      Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002; 116:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/105\">",
"      Alexander WS, Lyman SD, Wagner EF. Expression of functional c-kit receptors rescues the genetic defect of W mutant mast cells. EMBO J 1991; 10:3683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/106\">",
"      Tsuji K, Lyman SD, Sudo T, et al. Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 1992; 79:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/107\">",
"      Tsuji K, Zsebo KM, Ogawa M. Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit. Blood 1991; 78:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/108\">",
"      Metcalf D, Nicola NA. Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: effects of combination with colony-stimulating factors. Proc Natl Acad Sci U S A 1991; 88:6239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/109\">",
"      Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/110\">",
"      Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/111\">",
"      Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 1994; 91:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/112\">",
"      Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993; 75:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/113\">",
"      Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/114\">",
"      Lawrence HJ, Helgason CD, Sauvageau G, et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 1997; 89:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/115\">",
"      Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/116\">",
"      Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/117\">",
"      Moore MA. Haemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surv 1990; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/118\">",
"      Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/119\">",
"      Metcalf D, Willson TA, Hilton DJ, et al. Production of hematopoietic regulatory factors in cultures of adult and fetal mouse organs: measurement by specific bioassays. Leukemia 1995; 9:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/120\">",
"      Quesenberry PJ, Crittenden RB, Lowry P, et al. In vitro and in vivo studies of stromal niches. Blood Cells 1994; 20:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/121\">",
"      Sieff CA, Tsai S, Faller DV. Interleukin 1 induces cultured human endothelial cell production of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1987; 79:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/122\">",
"      Sieff CA, Niemeyer CM, Mentzer SJ, Faller DV. Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 1988; 72:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/123\">",
"      Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/124\">",
"      Yokota T, Arai N, de Vries J, et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev 1988; 102:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/125\">",
"      Arai KI, Lee F, Miyajima A, et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/126\">",
"      Niemeyer CM, Sieff CA, Mathey-Prevot B, et al. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood 1989; 73:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/127\">",
"      Wimperis JZ, Niemeyer CM, Sieff CA, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. Blood 1989; 74:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/128\">",
"      Cerdan C, Razanajaona D, Martin Y, et al. Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene. J Immunol 1992; 149:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/129\">",
"      Horii Y, Muraguchi A, Suematsu S, et al. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol 1988; 141:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/130\">",
"      Yang YC. Interleukin 11: an overview. Stem Cells 1993; 11:474.",
"     </a>",
"    </li>",
"    <li>",
"     Turner KJ, Clark SC. Interleukin-11: Biological and Clinical Perspectives. In: Hematopoietic Growth Factors in Clinical Applications, Mertelsmann R, Herrmann F (Eds), Marcel Dekker, New York 1995. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/132\">",
"      Yang L, Yang YC. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells. J Biol Chem 1994; 269:32732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/133\">",
"      Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/44/6858/abstract/134\">",
"      Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991; 7:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8380 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6858=[""].join("\n");
var outline_f6_44_6858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1305306\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF MYELOPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Granulocyte and macrophage colony-forming cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neutrophil production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Release of neutrophils into the blood compartment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REGULATION OF MYELOPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transcription factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PU.1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - C/EBP family",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Core binding factor family",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Retinoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Effects on progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effects on mature cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stem cell factor and flt3 ligand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Homeobox genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      REGULATION OF HEMATOPOIETIC GROWTH FACTOR GENES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1305306\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8380|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8380|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/58/31651\" title=\"figure 1\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/23/43376\" title=\"figure 2\">",
"      Extravasation of circulating leukocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/60/29647\" title=\"figure 3\">",
"      Transcription fx myelopoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/30/16876\" title=\"table 1\">",
"      Myelopoiesis knockouts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=related_link\">",
"      Definition and mechanisms of leukocytosis and neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_44_6859="Risk cats patients with LM";
var content_f6_44_6859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk categories in patients with leptomeningeal metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Poor risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Good risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS &lt;60",
"       </td>",
"       <td>",
"        KPS &ge;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple, fixed neurologic deficits",
"       </td>",
"       <td>",
"        Minimal or no fixed neurologic deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive systemic cancer without good treatment options",
"       </td>",
"       <td>",
"        Effective systemic treatment of cancer possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy or bulky CNS disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     KPS: Karnofsky Performance Status score.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with data from: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 1. 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6859=[""].join("\n");
var outline_f6_44_6859=null;
var title_f6_44_6860="Initiation ADHD drugs";
var content_f6_44_6860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for initiation of pharmacotherapy in children with ADHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Diagnostic assessment is complete and confirms diagnosis of ADHD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child is age six years or older*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parents accept medication as a contribution to management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School will cooperate in administration and monitoring",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No previous sensitivity to the chosen medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child has normal heart rate and blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child is seizure free",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child does not have Tourette syndrome",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child does not have pervasive developmental delay",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child does not have significant anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse among household members is not a concern (for children who will be treated with immediate release stimulants)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: attention deficit hyperactivity disorder.",
"     <br/>",
"     * Children younger than six years should be managed by or in consultation with a specialist since the effects of stimulants on preschool children are unpredictable.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     It is not safe to permit the child or adolescent to take his or her own medication to school.",
"     <br/>",
"     &Delta; Children with these conditions should be managed by, or in consultation with a specialist.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Atomoxetine, osmotic release methylphenidate, or the methylphenidate patch are alternatives to immediate-release stimulant preparations for children who live in households where substance abuse is a concern.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hill T, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6860=[""].join("\n");
var outline_f6_44_6860=null;
var title_f6_44_6861="ILD diagnosis and mortality";
var content_f6_44_6861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnosis and mortality in a series of children with interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients (n)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dead (n)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Specific",
"diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection/no bronchiolitis obliterans",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiolitis obliterans/adenovirus",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiolitis obliterans/no adenovirus",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypersensitivity pneumonitis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary vascular disease",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphocytic interstitial pneumonitis",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desquamative interstitial pneumonitis",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Usual interstitial pneumonitis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspiration",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemosiderosis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphangiomatosis",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Connective-tissue disease",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary infiltrates with eosinophilia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miscellaneous (BOOP, IBD, PAP, PM, BCG, lymphoma)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Suggestive diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypersensitivity pneumanitis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Miscellaneous (aspiration, sarcoidosis, EBV, LIP)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        No",
"specific diagnosis",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BOOP: bronchiolitis obliterans organizing pneumonia; IBD: inflammatory bowel disease; PAP: pulmonary alveolar proteinase; PM: pulmonary microlithiasis; BCG: bronchocentric granulomatosis; EBV: Epstein-Barr virus; LIP: lymphocytic interstitial pneumonitis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med 1997; 156:939. Official Journal of the American Thoracic Society. Copyright &copy;1997 American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6861=[""].join("\n");
var outline_f6_44_6861=null;
var title_f6_44_6862="CBTRUS incidence of primary CNS tumors";
var content_f6_44_6862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of all primary brain and CNS tumors by site",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"70%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Tumors of neuroepithelial tissue",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        54,301",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        34.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pilocytic astrocytoma",
"       </td>",
"       <td>",
"        2625",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protoplasmic and fibrillary astrocytoma",
"       </td>",
"       <td>",
"        854",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic astrocytoma",
"       </td>",
"       <td>",
"        3385",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unique astrocytoma variants",
"       </td>",
"       <td>",
"        753",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Astrocytoma, NOS",
"       </td>",
"       <td>",
"        3695",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioblastoma",
"       </td>",
"       <td>",
"        27,040",
"       </td>",
"       <td>",
"        17.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligodendroglioma",
"       </td>",
"       <td>",
"        2269",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic oligodendroglioma",
"       </td>",
"       <td>",
"        1031",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ependymoma/anaplastic ependymoma",
"       </td>",
"       <td>",
"        2147",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ependymoma variants",
"       </td>",
"       <td>",
"        798",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed glioma",
"       </td>",
"       <td>",
"        1573",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glioma malignant, NOS",
"       </td>",
"       <td>",
"        3516",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choroid plexus",
"       </td>",
"       <td>",
"        351",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroepithelial",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-malignant and malignant neuronal/glial",
"       </td>",
"       <td>",
"        2250",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineal parenchymal",
"       </td>",
"       <td>",
"        279",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Embryonal/primitive/medulloblastoma",
"       </td>",
"       <td>",
"        1564",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Tumors of cranial and spinal nerves",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        13,735",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        8.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nerve sheath, non-malignant and malignant",
"       </td>",
"       <td>",
"        13,733",
"       </td>",
"       <td>",
"        8.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Tumors of meninges",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        55,432",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        35.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningioma",
"       </td>",
"       <td>",
"        53,455",
"       </td>",
"       <td>",
"        33.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other mesenchymal, non-malignant and malignant",
"       </td>",
"       <td>",
"        631",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioblastoma",
"       </td>",
"       <td>",
"        1346",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Lymphomas and hematopoietic neoplasms",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        3855",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphoma",
"       </td>",
"       <td>",
"        3855",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Germ cell tumors and cysts",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        642",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Germ cell tumors, cysts and heterotopias",
"       </td>",
"       <td>",
"        642",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Tumors of sellar region",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        21,287",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        13.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary",
"       </td>",
"       <td>",
"        20,131",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Craniopharyngioma",
"       </td>",
"       <td>",
"        1156",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Local extensions from regional tumors",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        156",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chordoma/chondrosarcoma",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        Unclassified tumors",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        8680",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <br/>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioma",
"       </td>",
"       <td>",
"        1161",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neoplasm, unspecified",
"       </td>",
"       <td>",
"        7443",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        All other",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         TOTAL",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         158,088",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         100.0",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CBTRUS Statistical Report: NPCR and SEER Data from 2004-2006.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: CBTRUS (2010) Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States, Hinsdale, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6862=[""].join("\n");
var outline_f6_44_6862=null;
var title_f6_44_6863="Stand on one foot video";
var content_f6_44_6863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/80218/Stand_on_one_foot_movie.mp4?title=Stand+on+one+foot+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance exercise video: Stand on one foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    You can do this exercise while waiting for the bus or standing in line at the grocery. For an added challenge, you can modify the exercise to improve your balance.",
"    <br>",
"     <ol>",
"      <li>",
"       Stand on one foot behind a sturdy chair, holding on for balance.",
"      </li>",
"      <li>",
"       Hold position for up to 10 seconds.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times with other leg.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 more times with each leg.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_44_6863=[""].join("\n");
var outline_f6_44_6863=null;
